Document:

EX-10.1

 Exhibit 10.1 

SETTLEMENT AGREEMENT 

This Settlement Agreement (Agreement) is entered into among: (a) the United States of America, acting through the United States
Department of Justice and on behalf of the Office of Inspector General (OIG-HHS) of the Department of Health and Human Services (HHS) (collectively, the “United States”); (b) Amedisys, Inc. and Amedisys Holding, LLC (collectively,
“Amedisys”); and (c) April Nicole Brown, CAF Partners (including all individual partners of or other individuals associated with CAF Partners, each of whom individually and collectively agrees to this Agreement), Shelby L. Umberhandt,
Natalie Raven, Christy Curtis, Ellen Maffit, Brion Frix, Margaret Ognen, Malcolm Dulock, MD, and Charles H. Lewis, Jr. (collectively, “Relators”), through their authorized representatives. Hereafter, the United States, Amedisys, and
Relators are collectively referred to as the “Parties.” 
 I. RECITALS 

A. Headquartered in Baton Rouge, Louisiana, Amedisys is a for-profit national company that provides home health care services, including
nursing care and physical, speech, and occupational therapy, primarily for Medicare beneficiaries. 
 B. Pursuant to the qui tam
provisions of the False Claims Act, 31 U.S.C. § 3730(b), certain persons have filed civil actions against Amedisys, at least some of which include allegations that are encompassed by the “Covered Conduct” referenced in Paragraphs
I.D.1 through I.D.2. The civil actions enumerated in Paragraphs I.B.1 through I.B.7 are collectively referred to as the “Civil Actions.” 

  

 1. On January 22, 2010, April Nicole Brown filed a qui tam action in the United
States District Court for the Northern District of Alabama, captioned United States ex rel. April Nicole Brown v. Amedisys, Inc., Amedisys Home Health, Inc. of Alabama, original Civil Action Number CV-10-BE-0135-S (UNDER SEAL),
pursuant to the qui tam provisions of the False Claims Act, 31 U.S.C. § 3730(b). Brown filed a First Amended Complaint on or about April 5, 2012. 

2. On May 18, 2010, CAF Partners filed a qui tam action in the United States District Court for the Eastern District of
Pennsylvania captioned United States ex rel. CAF Partners and CAF Partners, individually v. Amedisys, Inc. and Ernst & Young, LLP, Civil Action Number 2-10-cv-002323 (UNDER SEAL), pursuant to the qui tam provisions of the
False Claims Act, 31 U.S.C. § 3730(b). CAF Partners filed a First Amended Complaint on or about October 27, 2010, a Second Amended Complaint on or about August 10, 2011, and a Third Amended Complaint on or about May 24, 2012.

 3. On February 15, 2011, Shelby L. Umberhandt filed a qui tam action in the United States District Court for the Northern
District of Georgia, captioned United States ex rel. Shelby L. Umberhandt, Relator, and Shelby L. Umberhandt, Plaintiff, v. Amedisys, Inc., original Civil Action Number 4 11-CV-0041-HLM (UNDER SEAL), pursuant to the qui tam provisions
of the False Claims Act, 31 U.S.C. § 3730(b). Umberhandt filed a First Amended Complaint on or about May 20, 2011.  
 4. On
March 29, 2011, Natalie Raven and Christy Curtis filed a qui tam action in the United States District Court for the Northern District of Georgia, captioned United States ex rel. Natalie Raven and Christy Curtis, State of Georgia ex
rel. Natalie Raven and Christy Curtis v. Amedisys, Inc., et al., Civil Action Number 1 11-CV-0994 (UNDER SEAL), pursuant to the qui tam provisions of the False Claims Act, 31 U.S.C. § 3730(b), and the Georgia Taxpayer Protection
False Claims Act, 23-3-120 to 23-3-127, as amended GA L. 2013, p. 141. Raven and Curtis filed a First Amended Complaint on or about November 13, 2012.  

  
 2 

 5. On June 17, 2011, Ellen Maffit and Brion Frix filed a qui tam action in the United
States District Court for the Northern District of Georgia, captioned United States ex rel. Ellen Maffit and Brion Frix, State of Georgia ex rel. Ellen Maffit and Brion Frix v. Amedisys, Inc., original Civil Action Number 1 11-CV-1976 (UNDER
SEAL), pursuant to the qui tam provisions of the False Claims Act, 31 U.S.C. § 3730(b), and the Georgia Taxpayer Protection False Claims Act, 23-3-120 to 23-3-127, as amended GA L. 2013, p. 141. 

6. On July 22, 2011, Margaret Ognen and Malcolm Dulock, MD filed a qui tam action in the United States District Court for the
Northern District of Georgia, captioned United States ex rel. Margaret Ognen and Malcolm Dulock, MD v. Amedisys, Inc., Amedisys Georgia, LLC, Amedisys Holding, LLC, Amedisys Hospice, LLC, Amedisys Northwest, LLC, Northside Hospital, Inc.
(d/b/a Northside Hospital – Forsyth), Dr. Daulton E. Todd, Jr., Daulton E. Todd, Jr., M.D., P.C., original Civil Action Number 1 11-CV-2421 (UNDER SEAL), pursuant to the qui tam provisions of the False Claims Act, 31 U.S.C.
§ 3730(b). Ognen and Dulock filed a First Amended Complaint on or about June 21, 2013, and a Second Amended Complaint on or about April 18, 2014. 

7. On March 23, 2012, Charles H. Lewis, Jr. filed a qui tam action in the United States District Court for the Western District of
New York, captioned United States, State of California, State of Colorado, State of Connecticut, State of Delaware, District of Columbia, State of Florida, State of Georgia, State of Illinois, State of

  
 3 

 
Indiana, State of Iowa, State of Louisiana, State of Maryland, Commonwealth of Massachusetts, State of Minnesota, State of New Hampshire, State of New Jersey, State of New Mexico, State of New
York, State of North Carolina, State of Oklahoma, State of Rhode Island, State of Tennessee, State of Texas, Commonwealth of Virginia, and the State of Wisconsin, ex rel. Charles H. Lewis, Jr. vs. Amedisys, Inc., original Civil Action Number 12
CV 0237 (UNDER SEAL), pursuant to the qui tam provisions of the False Claims Act, 31 U.S.C. § 3730(b), and false claims provisions enacted in each of the plaintiff states. 

C. The United States contends that Amedisys submitted or caused to be submitted claims for payment to the Medicare Program (Medicare), Title
XVIII of the Social Security Act, 42 U.S.C. §§ 1395-1395kkk-1. 
 D. 1. The United States contends that it has certain civil claims
arising from the Amedisys care centers identified in Exhibit A improperly billing and failing to refund overpayments for Medicare home health care services that Amedisys: (a) provided to non-homebound patients, (b) provided to patients
lacking a need for skilled nursing and/or skilled therapy services, (c) provided to patients without regard to medical necessity, and (d) overbilled by upcoding patients’ diagnoses, during the period from January 1, 2008 through
December 31, 2010. That conduct is referred to below as the “Primary Covered Conduct.” 
 2. The United States further
contends that it has certain civil claims arising from Amedisys’s billings to the Medicare program, during the period from April 1, 2008 through April 30, 2012, in violation of the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b, and
the Stark Law, 42 U.S.C. § 1395nn, for home health services referred by 

  
 4 

 
Georgia Cancer Specialists I, PC while Amedisys was providing Georgia Cancer Specialists I, PC remuneration that was not consistent with fair market value in the form of patient care coordination
services performed by Amedisys employees. That conduct is referred to below as the “Secondary Covered Conduct.” 
 3.
Collectively, the conduct referenced in Paragraphs I.D.1 through I.D.2 is referred to as the “Covered Conduct.” 
 E. This
Agreement is neither an admission of liability by Amedisys nor a concession by the United States or the Relators that their claims are not well founded. Amedisys expressly denies the allegations of the United States and the Relators as set forth
herein and in the Civil Actions. 
 F. Relators and/or their counsel claim entitlement under 31 U.S.C. § 3730(d) to a share of the
proceeds of this Agreement and to Relators’ reasonable expenses, attorneys’ fees, and costs. Relator Shelby L. Umberhandt has a claim against Amedisys under 31 U.S.C. § 3730(h). 

G. To avoid the delay, uncertainty, inconvenience, and expense of protracted litigation of the above claims, and in consideration of the mutual
promises and obligations of this Agreement, the Parties agree and covenant as follows: 
 II. TERMS AND CONDITIONS 

1. A. In total, Amedisys agrees to pay the United States the principal sum of $150,000,000.00 (150 million dollars), plus interest accruing
thereon from October 4, 2013, at a rate of 2.25 percent per annum (collectively, the principal and interest are the “Settlement Amount”), such amount to be paid in two (2) installments as set forth in Paragraphs 1.B and C. 

  
 5 

 B. Amedisys will make a payment to the United States in the amount of $115,000,000.00 (115
million dollars), plus interest accruing thereon from October 4, 2013, at a rate of 2.25 percent per annum, within seven (7) business days after the Effective Date of this Agreement, pursuant to written instructions to be provided by the
United States. 
 C. Not later than six (6) months after the Effective Date of this Agreement, Amedisys will pay the remaining
$35,000,000 (35 million dollars), plus interest accruing thereon from October 4, 2013, at a rate of 2.25 percent per annum, pursuant to written instructions to be provided by the United States. 

2. A. Conditioned upon the United States receiving from Amedisys the payment set forth in Paragraph II.1.B, and as soon as feasible after
receipt, the United States shall pay the following by electronic funds transfer: 
 1. $5,032,696.46, plus interest accruing thereon from
October 4, 2013, at a rate of 2.25 percent per annum, to April Nicole Brown; 
 2. $14,330,584.86, plus interest accruing thereon from
October 4, 2013, at a rate of 2.25 percent per annum, to CAF Partners (collectively); 
 3. $159,743.32, plus interest accruing thereon
from October 4, 2013, at a rate of 2.25 percent per annum, to Shelby L. Umberhandt; 
 4. $358,680.76, plus interest accruing thereon
from October 4, 2013, at a rate of 2.25 percent per annum, to Natalie Raven; and 
 5. $358,680.75, plus interest accruing thereon from
October 4, 2013, at a rate of 2.25 percent per annum, to Christy Curtis. 

  
 6 

 B. Conditioned upon the United States receiving from Amedisys the payment set forth in Paragraph
II.1.C, and as soon as feasible after receipt, the United States shall pay the following by electronic funds transfer: 
 1. $ 1,531,690.23,
plus interest accruing thereon from October 4, 2013, at a rate of 2.25 percent per annum, to April Nicole Brown; 
 2. $4,361,482.35,
plus interest accruing thereon from October 4, 2013, at a rate of 2.25 percent per annum, to CAF Partners (collectively); 
 3.
$48,617.53, plus interest accruing thereon from October 4, 2013, at a rate of 2.25 percent per annum, to Shelby L. Umberhandt; 
 4.
$109,163.71, plus interest accruing thereon from October 4, 2013, at a rate of 2.25 percent per annum, to Natalie Raven; and 
 5.
$109,163.71, plus interest accruing thereon from October 4, 2013, at a rate of 2.25 percent per annum, to Christy Curtis. 
 C. Amedisys
agrees to pay Relators and Relators’ counsel in full satisfaction of their claims for expenses, attorneys’ fees, and costs under 31 U.S.C. § 3730(d) and Relator Shelby L. Umberhandt’s claim under 31 U.S.C. § 3730(h),
pursuant to separate written agreements, no later than ten (10) business days after the Effective Date of this Agreement, by electronic funds transfer pursuant to written instructions to be provided by Relators’ counsel. No other payments
shall be made by Amedisys to Relators or Relators’ counsel with respect to the matters covered by this Agreement. Relator CAF Partners (including all individual partners of or other individuals associated with CAF Partners, each of whom
individually and collectively agrees to this Agreement) represents and warrants that it has assigned and transferred all 

  
 7 

 
claims for expenses, attorneys’ fees, and costs to its counsel, Kenney & McCafferty, Durrell Law Office, and Thomas & Associates. Relator Charles H. Lewis, Jr. represents
and warrants that he has assigned and transferred all claims for expenses, attorneys’ fees, and costs to his counsel, Mueller Law, LLC and Seiger Gfeller Laurie, LLP. Relator April Nicole Brown represents and warrants that she has assigned and
transferred all claims for expenses, attorneys’ fees, and costs to her counsel, Frohsin & Barger, LLC. Relators Margaret Ognen and Malcom Dulock, MD, represent and warrant that they have assigned and transferred all claims for
expenses, attorneys’ fees, and costs to their counsel, Gorby Peters & Associates, LLC. Those claims are included in the claims being resolved through the separate written agreements referenced in this paragraph. 

3. A. Subject to the exceptions in Paragraph II.6 (concerning excluded claims), and conditioned upon Amedisys’s full payment of the
Settlement Amount, the United States releases Amedisys, together with its current and former parent corporations; direct and indirect subsidiaries; brother and sister corporations; divisions; affiliates; current and former owners; current and
former officers, directors, and employees; and the successors and assigns of any of them, from any civil or administrative monetary claim the United States has for the Primary Covered Conduct under the False Claims Act, 31 U.S.C. §§
3729-3733; the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a; the Program Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-3812; any other statute creating causes of action for civil damages or civil penalties for which the Civil
Division of the Department of Justice has actual and present authority to assert and compromise pursuant to 28 C.F.R. Part 0, Subpart I, Section 0.45(d); or the common law theories of payment by mistake, unjust enrichment, fraud, disgorgement,
conversion, and misrepresentation. 

  
 8 

 B. Subject to the exceptions in Paragraph II.6 (concerning excluded claims), and conditioned upon
Amedisys’s full payment of the Settlement Amount, the United States releases Amedisys, together with its current and former parent corporations; direct and indirect subsidiaries; brother and sister corporations; divisions; affiliates;
current and former owners; current and former officers, directors, and employees; and the successors and assigns of any of them, from any civil or administrative monetary claim the United States has for the Secondary Covered Conduct under the False
Claims Act, 31 U.S.C. §§ 3729-3733; the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a; the Program Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-3812; the Stark Law, 42 U.S.C. § 1395nn(g)(3); any other statute
creating causes of action for civil damages or civil penalties for which the Civil Division of the Department of Justice has actual and present authority to assert and compromise pursuant to 28 C.F.R. Part 0, Subpart I, Section 0.45(d); or the
common law theories of payment by mistake, unjust enrichment, fraud, disgorgement, conversion, and misrepresentation. 
 4. A. In
consideration of the obligations of Amedisys in this Agreement, and conditioned upon Amedisys’s full payment of the Settlement Amount, and full payment of the amounts identified in the separate agreements referenced in Paragraph II.2.C. above
for claims under 31 U.S.C. § 3730(d) or (h), Relators, for themselves and for their heirs, successors, attorneys, agents, and assigns, release Amedisys, its predecessors, and its current and former divisions, parents, affiliates, subsidiaries,
successors, and assigns, and their current and former directors, officers, and employees (“Amedisys Parties”) 

  
 9 

 
from any claims or allegations that Relators asserted or could have asserted, arising from the Covered Conduct and from all liability, claims, demands, actions, or causes of action whatsoever,
whether known or unknown, fixed or contingent, in law or in equity, in contract or in tort, under any federal or state statute or regulation, or in common law, that Relators would have standing to bring in any capacity as of the Effective Date of
this Agreement (“Relators’ Claims”). Relators represent and warrant that, with the exception of those claims discussed in Paragraph II.2.C for expenses, attorneys’ fees, and costs that have been assigned and transferred to
Relators’ counsel, Relators have not assigned or transferred any of Relators’ Claims to any person, entity, or thing, and Relators covenant and agree not to assert or pursue any of Relators’ Claims in any way. Relators acknowledge
that they may later discover facts different from or in addition to those which they or their attorneys now know or believe to be true. It is the intention of Relators to fully, finally, and forever settle and release all claims included in the
releases set forth herein. The releases provided herein shall remain in effect notwithstanding the discovery or existence of any additional or different facts or the occurrence of any future events, circumstances or conditions. Relators expressly
waive any and all provisions, rights, or benefits conferred by California Civil Code Section 1542 and by any law of any state or territory in the United States, or principle of common law, which is similar, comparable, or equivalent to
California Civil Code Section 1542, which provides: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her
must have materially affected his or her settlement with the debtor.” Relators’ Claims that are released include but are not limited to any claims by Relators, Relators’ counsel, 

  
 10 

 
or the heirs, successors, attorneys, agents, or assigns of any of them against any Amedisys Parties arising from the filing of the Civil Actions or the negotiation of this Agreement or the
agreements referenced in Paragraph II.2.C above, under 31 U.S.C. § 3730(d) or (h) for expenses, attorneys’ fees, and costs. Relators and Relators’ counsel expressly reserve any claims against non-Amedisys Parties, and any
defenses related to any claims brought by non-Amedisys Parties. 
 B. Relators and their counsel further agree not to disseminate any
documents (whether in hardcopy or electronic format) in their possession or control that can be readily identified as having been created in whole or in part by, or at the direction of, Amedisys, its predecessors, or its current or former divisions,
parents, affiliates, subsidiaries, successors, or assigns, or their current or former directors, officers, or employees (“Amedisys Documents”). In this regard, Relators and their counsel will make a good faith effort to identify all such
Amedisys Documents. The obligations in this subparagraph do not apply: (1) to the extent that compliance with the obligations would conflict with a statute or regulation; (2) if disclosure of Amedisys Documents or information related
thereto is required by a subpoena or court order; (3) in the case of any Relator who is a current employee of Amedisys, but only to the degree they are authorized by Amedisys to utilize business records as necessary within the scope of their
current employment; (4) to the extent Amedisys Documents are available in the public domain; (5) to the extent Amedisys Documents or information related thereto are requested by or provided to any governmental entity, agency, or
representative, or any agent or contractor acting on behalf of a governmental entity; (6) to the extent Relators Natalie Raven and Christy Curtis or their counsel utilize documents in connection with

  
 11 

 
the case of United States ex rel. Natalie Raven and Christy Curtis, State of Georgia ex rel. Natalie Raven and Christy Curtis v. Amedisys, Inc., et al., Civil Action Number 1
11-CV-0994 (UNDER SEAL); or (7) to the extent Relators Margaret Ognen and Malcolm Dulock, MD or their counsel utilize documents in connection with the case of United States ex rel. Margaret Ognen and Malcolm Dulock, MD v. Amedisys, Inc.,
Amedisys Georgia, LLC, Amedisys Holding, LLC, Amedisys Hospice, LLC, Amedisys Northwest, LLC, Civil Action Number 1 11-CV-2421 (UNDER SEAL), as amended or re-filed, or in any state, federal or administrative action that relates to the factual
allegations contained therein. 
 C. Paragraph II.4 shall not in any way prevent Relators from disclosing any information or providing any
advice or assistance to any governmental agency or entity, representative, agent, or contractor. 
 5. A. In consideration of the
obligations of Amedisys in this Agreement and the Corporate Integrity Agreement (CIA), entered into between OIG-HHS and Amedisys, and conditioned upon Amedisys’s full payment of the Settlement Amount, OIG-HHS agrees to release and refrain from
instituting, directing, or maintaining any administrative action seeking exclusion from Medicare, Medicaid, and other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) against Amedisys, including any of the Amedisys care
centers identified in Exhibit A, under 42 U.S.C. § 1320a-7a (Civil Monetary Penalties Law) or 42 U.S.C. § 1320a-7(b)(7) (permissive exclusion for fraud, kickbacks, and other prohibited activities) for the Covered Conduct, except as
reserved in Paragraph II.6 (concerning excluded claims), below, and as reserved in this Paragraph. OIG-HHS expressly reserves all rights to comply with any statutory obligations to 

  
 12 

 
exclude Amedisys from Medicare, Medicaid, and other Federal health care programs under 42 U.S.C. § 1320a-7(a) (mandatory exclusion) based upon the Covered Conduct. Nothing in this Paragraph
precludes OIG-HHS from taking action against entities or persons, or for conduct and practices, for which claims have been reserved in Paragraph II.6. 

B. Notwithstanding the foregoing, in the event Amedisys fails to pay any amount as provided in Paragraph II.1 within seven (7) business
days of the date upon which such payment is due, Amedisys shall be in Default of its payment obligations (“Default”). In the event of Default, OIG-HHS may exclude Amedisys from participating in all Federal health care programs until
Amedisys pays the Settlement Amount as set forth in Paragraph II.1 and reasonable costs. Prior to any such exclusion, OIG-HHS will provide written notice of Default to Amedisys, and Amedisys shall be given five (5) business days to cure
the Default. If Amedisys fails to cure the Default within five (5) business days of receiving written notice of Default from OIG-HHS, then OIG-HHS will provide written notice of any such exclusion to Amedisys, and Amedisys waives any further
notice of the exclusion under 42 U.S.C. § 1320a-7(b)(7), and agrees not to contest such exclusion either administratively or in any state or federal court. Reinstatement to program participation is not automatic. If at the end of the
period of exclusion Amedisys wishes to apply for reinstatement, Amedisys must submit a written request for reinstatement to OIG-HHS in accordance with the provisions of 42 C.F.R. §§ 1001.3001-3005. Amedisys will not be reinstated
unless and until OIG-HHS approves such request for reinstatement. 

  
 13 

 6. Notwithstanding the releases given in Paragraphs II.3 and II.4 of this Agreement, or any other
term of this Agreement, the following claims of the United States are specifically reserved and are not released: 
  

	 	a.	Any liability arising under Title 26, U.S. Code (Internal Revenue Code); 

  

	 	b.	Any criminal liability; 

  

	 	c.	Except as explicitly stated in this Agreement, any administrative liability, including mandatory exclusion from Federal health care programs; 

 

	 	d.	Any liability to the United States (or its agencies) for any conduct other than the Covered Conduct; 

  

	 	e.	Any liability based upon obligations created by this Agreement; 

  

	 	f.	Any liability for failure to deliver goods or services due; and 

  

	 	g.	Any liability for personal injury or property damage or for other consequential damages arising from the Covered Conduct. 

7. Relators and their heirs, successors, attorneys, agents, and assigns shall not object to this Agreement but agree and confirm that the
Agreement is fair, adequate, and reasonable under all the circumstances, and expressly waive the opportunity for a hearing on any objections to the Agreement pursuant to 31 U.S.C. § 3730(c)(2)(B). Conditioned upon receipt of the payments
described in Paragraphs II.2.A and II.2.B by April Nicole Brown, CAF Partners, Shelby L. Umberhandt, Natalie Raven, and Christy Curtis, Relators and their heirs, successors, attorneys, agents, and assigns fully and finally release, waive, and
forever discharge the United States, its agencies, officers, agents, 

  
 14 

 
employees, and servants, from any claims arising from the filing in the Civil Actions of the claims being dismissed pursuant to Paragraph II.15.A or under 31 U.S.C. § 3730, and from any
claims to a share of the proceeds of this Agreement and/or the claims in the Civil Actions being dismissed pursuant to Paragraph II.15.A. 

8. Amedisys waives and shall not assert any defenses Amedisys may have to any criminal prosecution or administrative action relating to the
Covered Conduct that may be based in whole or in part on a contention that, under the Double Jeopardy Clause in the Fifth Amendment of the Constitution, or under the Excessive Fines Clause in the Eighth Amendment of the Constitution, this Agreement
bars a remedy sought in such criminal prosecution or administrative action. Nothing in this paragraph or any other provision of this Agreement constitutes an agreement by the United States concerning the characterization of the Settlement Amount for
purposes of the Internal Revenue laws, Title 26 of the United States Code. 
 9. A. Amedisys fully and finally releases the United States,
its agencies, officers, agents, employees, and servants, from any claims (including attorneys’ fees, costs, and expenses of every kind and however denominated) that Amedisys has asserted, could have asserted, or may assert in the future against
the United States, its agencies, officers, agents, employees, and servants, related to the Covered Conduct and the United States’ investigation and prosecution thereof. 

B. In consideration of Relators’ obligations set forth in this Agreement, Amedisys, its predecessors, and its current and former
divisions, parents, affiliates, subsidiaries, successors, and assigns, and their current and former directors, officers, and employees when acting on behalf of Amedisys (collectively “the Amedisys Entities”),

  
 15 

 
fully and finally release, waive, and forever discharge each of the Relators and their respective heirs, individual partners, successors, attorneys, agents, and assigns, individually and
collectively, from any claims or allegations that the Amedisys Entities asserted or could have asserted, arising from the Covered Conduct and from all liability, claims, demands, actions, or causes of action whatsoever, whether known or unknown,
fixed or contingent, in law or in equity, in contract or in tort, under any federal or state statute or regulation, or in common law, that the Amedisys Entities would have standing to bring as of the Effective Date of this Agreement. The Amedisys
Entities acknowledge that they may later discover facts different from or in addition to those which they or their attorneys now know or believe to be true. It is the intention of the Amedisys Entities to fully, finally, and forever settle and
release all claims included in the releases set forth herein. The releases provided herein shall remain in effect notwithstanding the discovery or existence of any additional or different facts or the occurrence of any future events, circumstances
or conditions. Regarding any claims Relators or Relators’ counsel may have against non-Amedisys Parties, as reserved in Paragraph II.4.A, Amedisys reserves any related claims and defenses. 

10. The Settlement Amount shall not be decreased as a result of the denial of claims for payment now being withheld from payment by any
Medicare contractor (e.g., Medicare Administrative Contractor, fiscal intermediary, carrier) or any state payor, related to the Covered Conduct; and Amedisys agrees not to resubmit to any Medicare contractor or any state payor any previously
denied claims related to the Covered Conduct, and agrees not to appeal any such denials of claims. 

  
 16 

 11. Amedisys agrees to the following: 

a. Unallowable Costs Defined: All costs (as defined in the Federal Acquisition Regulation, 48 C.F.R. § 31.205-47; and in Titles XVIII and
XIX of the Social Security Act, 42 U.S.C. §§ 1395-1395kkk-1 and 1396-1396w-5; and the regulations and official program directives promulgated thereunder) incurred by or on behalf of Amedisys, its present or former officers, directors,
employees, shareholders, and agents in connection with: 
  

	 	(1)	the matters covered by this Agreement; 

  

	 	(2)	the United States’ audit(s) and civil investigation(s) of the matters covered by this Agreement; 

  

	 	(3)	Amedisys’s investigation, defense, and corrective actions undertaken in response to the United States’ audit(s) and civil investigation(s) in connection with the matters covered by this Agreement (including
attorney’s fees); 

  

	 	(4)	the negotiation and performance of this Agreement; 

  

	 	(5)	the payment Amedisys makes to the United States pursuant to this Agreement and any payments that Amedisys may make to Relators, including costs and attorney’s fees; and 

 

	 	(6)	the negotiation of, and obligations undertaken pursuant to the CIA to: 

  

	 	(i)	retain an independent review organization to perform reviews as described in the CIA; and 

  

	 	(ii)	prepare and submit reports to the OIG-HHS 

  
 17 

 are unallowable costs for government contracting purposes and under the Medicare Program, Medicaid Program,
TRICARE Program, and Federal Employees Health Benefits Program (FEHBP) (hereinafter referred to as Unallowable Costs). However, nothing in Paragraph II.11.a.(6) that may apply to the obligations undertaken pursuant to the CIA affects the status of
costs that are not allowable based on any other authority applicable to Amedisys. 
 b. Future Treatment of Unallowable Costs: Unallowable
Costs shall be separately determined and accounted for in nonreimbursable cost centers by Amedisys, and Amedisys shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or
seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Amedisys or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs. 

c. Treatment of Unallowable Costs Previously Submitted for Payment: Amedisys further agrees that within 90 days of the Effective Date of this
Agreement it shall identify to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and Medicaid and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph) included in payments previously sought
from the United States, or any State Medicaid program, including, but not limited to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted by Amedisys or any of its subsidiaries or
affiliates, and shall request, and agree, that such cost reports, cost statements, information reports, or payment requests, even if already settled, be adjusted to account for the effect of the inclusion of

  
 18 

 
the Unallowable Costs. Amedisys agrees that the United States, at a minimum, shall be entitled to recoup from Amedisys any overpayment plus applicable interest and penalties as a result of the
inclusion of such Unallowable Costs on previously-submitted cost reports, information reports, cost statements, or requests for payment. 

Any payments due after the adjustments have been made shall be paid to the United States pursuant to the direction of the Department of
Justice and/or the affected agencies. The United States reserves its rights to disagree with any calculations submitted by Amedisys or any of its subsidiaries or affiliates on the effect of inclusion of Unallowable Costs (as defined in this
Paragraph) on Amedisys or any of its subsidiaries or affiliates’ cost reports, cost statements, or information reports. 
 d. Nothing in
this Agreement shall constitute a waiver of the rights of the United States to audit, examine, or re-examine Amedisys’s books and records to determine that no Unallowable Costs have been claimed in accordance with the provisions of this
Paragraph. 
 12. This Agreement is intended to be for the benefit of the Parties only. The Parties do not release any claims against any
other person or entity, except to the extent provided for in Paragraph II.13 (concerning waivers for beneficiaries). 
 13. Amedisys agrees
that it waives and shall not seek payment for any of the health care billings covered by this Agreement from any health care beneficiaries or their parents, sponsors, legally responsible individuals, or third party payors based upon the claims
defined as Covered Conduct. 

  
 19 

 14. Amedisys warrants that it has reviewed its financial situation and that it currently is
solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and 548(a)(1)(B)(ii)(I), and shall remain solvent following payment to the United States of the Settlement Amount. Further, the Parties warrant that, in evaluating whether to execute
this Agreement, they (a) have intended that the mutual promises, covenants, and obligations set forth constitute a contemporaneous exchange for new value given to Amedisys, within the meaning of 11 U.S.C. § 547(c)(1), and (b) conclude
that these mutual promises, covenants, and obligations do, in fact, constitute such a contemporaneous exchange. Further, the Parties warrant that the mutual promises, covenants, and obligations set forth herein are intended to and do, in fact,
represent a reasonably equivalent exchange of value that is not intended to hinder, delay, or defraud any entity to which Amedisys was or became indebted to on or after the date of this transfer, within the meaning of 11 U.S.C. § 548(a)(1).

 15. A. Upon receipt of the payments described in Paragraphs II.1 and II.2.C, above, the United States and Relators shall promptly sign
and file in the Civil Actions Joint Stipulations dismissing all claims against Amedisys, Inc.; Amedisys Holding, LLC; Amedisys Home Health, Inc. of Alabama; Amedisys Georgia, LLC; Amedisys Hospice, LLC; and Amedisys Northwest, LLC, as follows: 

 

	 	a.	the Stipulations of Dismissal shall be with prejudice as to the Relators’ claims in the Civil Actions, pursuant to and consistent with the terms and conditions of this Agreement; 

 

	 	b.	the Stipulations of Dismissal shall be with prejudice as to the United States’ claims as to the Covered Conduct, pursuant to and consistent with the terms and conditions of this Agreement; and 

  
 20 

	 	c.	the Stipulations of Dismissal shall be without prejudice as to the United States as to all claims not for the Covered Conduct, pursuant to and consistent with the terms and conditions of this Agreement.

 16. Except for Relators’ claims for expenses, attorneys’ fees, and costs under 31 U.S.C. § 3730(d) and (h),
which are being resolved pursuant to separate written agreements as provided in Paragraph II.2.C above, each Party shall bear its own legal and other costs incurred in connection with this matter, including the preparation and performance of this
Agreement. 
 17. Each Party and signatory to this Agreement represents that it freely and voluntarily enters into this Agreement without
any degree of duress or compulsion. 
 18. This Agreement is governed by the laws of the United States. The exclusive jurisdiction and venue
for any dispute relating to this Agreement is the United States District Court for the Eastern District of Pennsylvania, except for any dispute related to United States ex rel. Natalie Raven and Christy Curtis, State of Georgia ex rel. Natalie
Raven and Christy Curtis v. Amedisys, Inc., et al., Civil Action Number 1 11-CV-0994 (UNDER SEAL), for which the exclusive jurisdiction and venue is the United States District Court for the Northern District of Georgia. For purposes of
construing this Agreement, this Agreement shall be deemed to have been drafted by all Parties to this Agreement and shall not, therefore, be construed against any Party for that reason in any subsequent dispute. 

19. This Agreement constitutes the complete agreement between the Parties, except as to: (a) the separate agreements referenced in
Paragraph II.2.C above; and (b) any separate agreement(s) entered into by and among certain Relators regarding Relators’ 
 redistribution of the
United States’ payments pursuant to 31 U.S.C. § 3730(d). This Agreement may not be amended except by written consent of the Parties. 

  
 21 

 20. The undersigned counsel represent and warrant that they are fully authorized to execute this
Agreement on behalf of the persons and entities indicated below. 
 21. This Agreement may be executed in counterparts, each of which
constitutes an original and all of which constitute one and the same Agreement. 
 22. This Agreement is binding on Amedisys’s
successors, transferees, heirs, and assigns. 
 23. This Agreement is binding on Relators’ successors, transferees, heirs, and assigns.

 24. All parties consent to the United States’ disclosure of this Agreement, and information about this Agreement, to the public.

 25. This Agreement is effective on the date of signature of the last signatory to the Agreement (Effective Date of this Agreement).
Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this Agreement. 

  
 22 

 THE UNITED STATES OF AMERICA 

 

							
	DATED: 4.23.14	 		 	BY:	 	 /s/ Lisa Katz Samuels

		 		 		 	 Lisa Katz Samuels
 Trial Attorney

		 		 		 	Commercial Litigation Branch
		 		 		 	Civil Division
		 		 		 	United States Department of Justice
				
	DATED: 4.23.14	 		 	BY:	 	 /s/ Bradley Brinkman

		 		 		 	 Bradley Brinkman
 Trial Attorney

		 		 		 	Commercial Litigation Branch
		 		 		 	Civil Division
		 		 		 	United States Department of Justice

  
 23 

							
	DATED: 4.23.14	 		 	BY:	 	 /s/ Zane David Memeger

		 		 		 	Zane David Memeger
		 		 		 	United States Attorney
				
	DATED: 4.23.14	 		 	BY:	 	 /s/ Margaret L. Hutchison

		 		 		 	Margaret L. Hutchison
		 		 		 	Assistant United States Attorney
		 		 		 	Chief, Civil Division
				
	DATED: 4.23.14	 		 	BY:	 	 /s/ Gregory B. David

		 		 		 	Gregory B. David
		 		 		 	Assistant United States Attorneys
				
	DATED: 4.23.14	 		 	BY:	 	 /s/ Eric D. Gill

		 		 		 	Eric D. Gill
		 		 		 	Assistant United States Attorneys

  
 24 

							
	DATED: 04.23.14	 		 	BY:	 	 /s/ Christopher J. Huber

		 		 		 	Christopher J. Huber
		 		 		 	Assistant United States Attorney
		 		 		 	Northern District of Georgia

  
 25 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Robert K. DeConti

		 		 		 	Robert K. DeConti
		 		 		 	Assistant Inspector General for Legal Affairs
		 		 		 	Office of Counsel to the Inspector General
		 		 		 	Office of Inspector General
		 		 		 	United States Department of Health and Human Services

  
 26 

 DEFENDANTS 
  

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Ronald A. LaBorde

		 		 		 	Ronald A. LaBorde
		 		 		 	Amedisys, Inc.
		 		 		 	Title: Interim Chief Executive Officer and President
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Ronald A. LaBorde

		 		 		 	Ronald A. LaBorde
		 		 		 	Amedisys Holding, LLC
		 		 		 	Title: Interim Chief Executive Officer and President
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Paul B. Murphy

		 		 		 	Paul B. Murphy, Esq.
		 		 		 	Richard L. Shackelford, Esq.
		 		 		 	Matthew H. Baughman, Esq.
		 		 		 	King & Spalding LLP

  
 27 

 RELATORS 
  

							
	DATED: 04.21.14	 		 	BY:	 	 /s/ April Nicole Brown

		 		 		 	April Nicole Brown
				
	DATED: 04.21.14	 		 	BY:	 	 /s/ James F. Barger, Jr.

		 		 		 	Henry I. Frohsin, Esq.
		 		 		 	James F. Barger, Jr., Esq.
		 		 		 	J. Elliott Walthall, Esq.
		 		 		 	Frohsin & Barger, LLC
		 		 		 	Counsel for April Nicole Brown

  
 28 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Diane Schulman Davidow

		 		 		 	CAF Partners
		 		 		 	By: Diane Schulman Davidow
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ M. Tavy Deming, Esq.

		 		 		 	M. Tavy Deming, Esq.
		 		 		 	Emily C. Lambert, Esq.
		 		 		 	Kenney & McCafferty
		 		 		 	Counsel for CAF Partners
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Suzanne E. Durrell, Esq.

		 		 		 	Suzanne E. Durrell, Esq.
		 		 		 	Durrell Law Office
		 		 		 	Counsel for CAF Partners
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Robert M. Thomas, Esq.

		 		 		 	Robert M. Thomas, Esq.
		 		 		 	Thomas & Associates
		 		 		 	Counsel for CAF Partners

  
 29 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Diane Schulman Davidow

		 		 		 	Diane Schulman Davidow
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ M. Tavy Deming, Esq.

		 		 		 	M. Tavy Deming, Esq.
		 		 		 	Emily C. Lambert, Esq.
		 		 		 	Kenney & McCafferty
		 		 		 	Counsel for Diane Schulman Davidow
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Suzanne E. Durrell, Esq.

		 		 		 	Suzanne E. Durrell, Esq.
		 		 		 	Durrell Law Office
		 		 		 	Counsel for Diane Schulman Davidow
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Robert M. Thomas, Esq.

		 		 		 	Robert M. Thomas, Esq.
		 		 		 	Thomas & Associates
		 		 		 	Counsel for Diane Schulman Davidow

  
 30 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Jock Ferguson

		 		 		 	Jock Ferguson
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ M. Tavy Deming, Esq.

		 		 		 	M. Tavy Deming, Esq.
		 		 		 	Emily C. Lambert, Esq.
		 		 		 	Kenney & McCafferty
		 		 		 	Counsel for Jock Ferguson
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Suzanne E. Durrell, Esq.

		 		 		 	Suzanne E. Durrell, Esq.
		 		 		 	Durrell Law Office
		 		 		 	Counsel for Jock Ferguson
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Robert M. Thomas, Esq.

		 		 		 	Robert M. Thomas, Esq.
		 		 		 	Thomas & Associates
		 		 		 	Counsel for Jock Ferguson

  
 31 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Annette Arvie

		 		 		 	Annette Arvie
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ M. Tavy Deming, Esq.

		 		 		 	M. Tavy Deming, Esq.
		 		 		 	Emily C. Lambert, Esq.
		 		 		 	Kenney & McCafferty
		 		 		 	Counsel for Annette Arvie
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Suzanne E. Durrell, Esq.

		 		 		 	Suzanne E. Durrell, Esq.
		 		 		 	Durrell Law Office
		 		 		 	Counsel for Annette Arvie
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Robert M. Thomas, Esq.

		 		 		 	Robert M. Thomas, Esq.
		 		 		 	Thomas & Associates
		 		 		 	Counsel for Annette Arvie

  
 32 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Thomas A. Fisher

		 		 		 	Thomas A. Fisher
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ M. Tavy Deming, Esq.

		 		 		 	M. Tavy Deming, Esq.
		 		 		 	Emily C. Lambert, Esq.
		 		 		 	Kenney & McCafferty
		 		 		 	Counsel for Thomas A. Fisher
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Suzanne E. Durrell, Esq.

		 		 		 	Suzanne E. Durrell, Esq.
		 		 		 	Durrell Law Office
		 		 		 	Counsel for Thomas A. Fisher
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Robert M. Thomas, Esq.

		 		 		 	Robert M. Thomas, Esq.
		 		 		 	Thomas & Associates
		 		 		 	Counsel for Thomas A. Fisher

  
 33 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Cynthia M. Dauner

		 		 		 	Cynthia M. Dauner
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ M. Tavy Deming, Esq.

		 		 		 	M. Tavy Deming, Esq.
		 		 		 	Emily C. Lambert, Esq.
		 		 		 	Kenney & McCafferty
		 		 		 	Counsel for Cynthia M. Dauner
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Suzanne E. Durrell, Esq.

		 		 		 	Suzanne E. Durrell, Esq.
		 		 		 	Durrell Law Office
		 		 		 	Counsel for Cynthia M. Dauner
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Robert M. Thomas, Esq.

		 		 		 	Robert M. Thomas, Esq.
		 		 		 	Thomas & Associates
		 		 		 	Counsel for Cynthia M. Dauner

  
 34 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Eric D. Fader

		 		 		 	Eric D. Fader
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ M. Tavy Deming, Esq.

		 		 		 	M. Tavy Deming, Esq.
		 		 		 	Emily C. Lambert, Esq.
		 		 		 	Kenney & McCafferty
		 		 		 	Counsel for Eric D. Fader
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Suzanne E. Durrell, Esq.

		 		 		 	Suzanne E. Durrell, Esq.
		 		 		 	Durrell Law Office
		 		 		 	Counsel for Eric D. Fader
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ Robert M. Thomas, Esq.

		 		 		 	Robert M. Thomas, Esq.
		 		 		 	Thomas & Associates
		 		 		 	Counsel for Eric D. Fader

  
 35 

							
	DATED: 04.21.14	 		 	BY:	 	 /s/ Shelby L. Umberhandt

		 		 		 	Shelby L. Umberhandt
				
	DATED: 04.21.14	 		 	BY:	 	 /s/ Kevin A. Doyle, Esq.

		 		 		 	Kevin A. Doyle, Esq.
		 		 		 	 Lokey, Mobley & Doyle LLP
 Counsel for
Shelby L. Umberhandt

  
 36 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Natalie Raven

		 		 		 	Natalie Raven
				
	DATED: 04.21.14	 		 	BY:	 	 /s/ Louis J. Cohen

		 		 		 	Louis J. Cohen, Esq.
		 		 		 	Louis J. Cohen, P.C.
		 		 		 	Counsel for Natalie Raven
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ G. Mark Simpson

		 		 		 	G. Mark Simpson, Esq.
		 		 		 	Simpson Law Firm, LLC
		 		 		 	Counsel for Natalie Raven

  
 37 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Christy Curtis

		 		 		 	Christy Curtis
				
	DATED: 04.21.14	 		 	BY:	 	 /s/ Louis J. Cohen

		 		 		 	Louis J. Cohen, Esq.
		 		 		 	Louis J. Cohen, P.C.
		 		 		 	Counsel for Christy Curtis
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ G. Mark Simpson

		 		 		 	G. Mark Simpson, Esq.
		 		 		 	Simpson Law Firm, LLC
		 		 		 	Counsel for Christy Curtis

  
 38 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Ellen Maffit

		 		 		 	Ellen Maffit
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ G. Mark Simpson

		 		 		 	G. Mark Simpson, Esq.
		 		 		 	Simpson Law Firm, LLC
		 		 		 	Counsel for Ellen Maffit

  
 39 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Brion Frix

		 		 		 	Brion Frix
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ G. Mark Simpson

		 		 		 	G. Mark Simpson, Esq.
		 		 		 	Simpson Law Firm, LLC
		 		 		 	Counsel for Brion Frix

  
 40 

							
	DATED: 04.21.14	 		 	BY:	 	 /s/ Margaret Ognen

		 		 		 	Margaret Ognen
				
	DATED: 04.21.14	 		 	BY:	 	 /s/ Mary Donne Peters

		 		 		 	Mary Donne Peters, Esq.
		 		 		 	Gorby Peters & Associates, LLC
		 		 		 	Counsel for Margaret Ognen

  
 41 

							
	DATED: 04.21.14	 		 	BY:	 	 /s/ Malcom Dulock, MD

		 		 		 	Malcolm Dulock, M.D.
				
	DATED: 04.21.14	 		 	BY:	 	 /s/ Mary Donne Peters

		 		 		 	Mary Donne Peters, Esq.
		 		 		 	Gorby Peters & Associates, LLC
		 		 		 	Counsel for Malcolm Dulock, M.D.

  
 42 

							
	DATED: 04.22.14	 		 	BY:	 	 /s/ Charles H. Lewis, Jr.

		 		 		 	Charles H. Lewis, Jr.
				
	DATED: 04.22.14	 		 	BY:	 	 /s/ William L. Hurlock

		 		 		 	William L. Hurlock, Esq.
		 		 		 	Mueller Law LLC
		 		 		 	Seiger Gfeller Laurie, LLP
		 		 		 	Counsel for Charles H. Lewis, Jr.

  
 43 

 EXHIBIT A 
  

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	Amedisys Home Health, Inc. of Alabama 
d/b/a Amedisys Home Health of Ozark	  	123 S Painter Avenue, Suite C	  	Ozark	  	AL	  	36360-1802	  	01-7159	  	1030
							
	Amedisys Home Health, Inc. of Alabama 
d/b/a Amedisys Home Health of Tuscaloosa	  	1300 McFarland Blvd., NE Suite 320	  	Tuscaloosa	  	AL	  	35406-2282	  	01-7300	  	1009
							
	Amedisys Home Health, Inc. of Alabama 
d/b/a Amedisys Home Health of Fayette	  	1616 Temple Ave. N	  	Fayette	  	AL	  	35555-1319	  	01-7300	  	1015
							
	Amedisys Home Health, Inc. of Alabama 
d/b/a Amedisys Home Health of Brent	  	10341 Hwy 5, Suite E	  	Brent	  	AL	  	35034-3917	  	01-7300	  	1022
							
	 Amedisys Home Health, Inc. of Alabama
 d/b/a
Amedisys Home Health of Gadsden
	  	400 West Meighan Boulevard, Suite 200	  	Gadsden	  	AL	  	35901-3214	  	01-7305	  	1021

  
 44 

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	 Amedisys Home Health, Inc. of Alabama
 d/b/a
Amedisys Home Health of Anniston
	  	171 Town Center Drive, MPS-4	  	Anniston	  	AL	  	36205-4101	  	01-7305	  	1012
							
	 Amedisys Home Health, Inc. of Alabama
 d/b/a
Amedisys Home Health of Sylacauga
	  	395 James Payton Boulevard	  	Sylacauga	  	AL	  	35150-8064	  	01-7305	  	1032
							
	 Amedisys Home Health, Inc. of Alabama
 d/b/a
Amedisys Home Health of Roanoke
	  	935 Highway 431, Unit 4	  	Roanoke	  	AL	  	36274-1736	  	01-7305	  	1033
							
	 Tender Loving Care Health Care Services of Florida, L.L.C.

d/b/a Amedisys Home Health
	  	751 Oak Street, Suite 301	  	Jacksonville	  	FL	  	32204-3376	  	10-3102	  	0467
							
	 Amedisys Florida, LLC
 d/b/a Amedisys Home
Health
	  	808 Oakfield Drive	  	Brandon	  	FL	  	33511-4949	  	10-7007	  	0412
							
	 Housecall Home Health, LLC
 d/b/a Amedisys Home
Health
	  	 700 Zeagler Dr.,

Suite 10
	  	Palatka	  	FL	  	32177-3826	  	10-8056	  	5466
							
	 Housecall Home Health, LLC
 d/b/a Amedisys Home
Health
	  	9200 NW 39th Avenue, Suite 190	  	Gainesville	  	FL	  	32606-7368	  	10-8056	  	5468

  
 45 

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	 Housecall Home Health, LLC
 d/b/a Amedisys Home
Health
	  	461 SW Main Blvd.	  	Lake City	  	FL	  	32025-5268	  	10-8056	  	5478
							
	 Housecall Home Health, LLC
 d/b/a Amedisys Home
Health
	  	1541 SW 1st Avenue, Suite 102	  	Ocala	  	FL	  	34471-6506	  	10-8056	  	5439
							
	 Housecall Home Health, Inc.
 d/b/a Amedisys of
North Central Florida
	  	109 NW 3rd Avenue	  	Chiefland	  	FL	  	32626-0841	  	10-8056	  	5476
							
	 Amedisys Georgia, L.L.C.
 d/b/a Coosa Valley
Home Health, an Amedisys Company
	  	160 Three Rivers Drive, NE, Suite 1100	  	Rome	  	GA	  	30161-2306	  	11-7041	  	3320
							
	 Amedisys Georgia, L.L.C.
 d/b/a Coosa Valley
Home Health, an Amedisys Company
	  	 12 Felton Place,

Suite E
	  	Cartersville	  	GA	  	30120-2165	  	11-7041	  	3322
							
	 Amedisys Georgia, L.L.C.
 d/b/a Coosa Valley
Home Health, an Amedisys Company
	  	401 N. Main Street	  	Cedartown	  	GA	  	30125-2643	  	11-7041	  	3321

  
 46 

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	 Amedisys Georgia, L.L.C.
 d/b/a Amedisys Home
Health of Covington
	  	4162 Baker Street NE	  	Covington	  	GA	  	30014-1404	  	11-7065	  	3302
							
	 Amedisys Georgia, L.L.C.
 d/b/a Amedisys Home
Health of Madison
	  	500 Great Oaks Drive, Suite 3	  	Monroe	  	GA	  	30655-8228	  	11-7065	  	3337
							
	 Amedisys Georgia, L.L.C.
 d/b/a Amedisys Home
Health of Athens
	  	1061 Dowdy Road, Suite 205	  	Athens	  	GA	  	30606-5700	  	11-7065	  	3362
							
	 Amedisys Home Health, Inc. of Alabama
 d/b/a
Amedisys Home Health of Citronelle
	  	19375 N. 3rd St, Ste 101	  	Citronelle	  	AL	  	36522-2048	  	01-7070	  	1006
							
	 Amedisys Home Health, Inc. of Alabama
 d/b/a
Amedisys Home Health of Citronelle
	  	19375 Third Street North, Suite 101	  	Citronelle	  	AL	  	35901-2048	  	01-7070	  	1025
							
	 Amedisys Louisiana, LLC
 d/b/a Amedisys Home
Health
	  	1201 Camellia Blvd., Suite 201	  	Lafayette	  	LA	  	70508-7228	  	19-7263	  	1253
							
	 Amedisys Louisiana, LLC
 d/b/a Amedisys Home
Health
	  	2341 Larkspur Lane, Suite 3	  	Opelousas	  	LA	  	70570-8664	  	19-7263	  	1292

  
 47 

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	 Amedisys Mississippi, LLC
 d/b/a Amedisys Home
Health of Collins
	  	18 Melody Lane	  	Collins	  	MS	  	39428-9002	  	25-7087	  	1407
							
	 Amedisys Mississippi, LLC
 d/b/a Amedisys Home
Health of Laurel
	  	512 North 13th Ave	  	Laurel	  	MS	  	39440-3825	  	25-7087	  	1410
							
	 Amedisys Mississippi, LLC
 d/b/a Amedisys Home
Health of Hattiesburg
	  	6184 US Highway 98 West, Suite 130	  	Hattiesburg	  	MS	  	39402-8530	  	25-7087	  	1409
							
	 Amedisys Mississippi, LLC
 d/b/a Amedisys Home
Health of Magee
	  	104 1st Avenue, SE	  	Magee	  	MS	  	39111-3516	  	25-7087	  	1416
							
	 Amedisys Oklahoma, LLC
 d/b/a Amedisys Home
Health
	  	14201 Caliber Drive, Suite 110	  	Oklahoma City	  	OK	  	73134-1027	  	37-7642	  	2038
							
	 Amedisys Oklahoma, LLC
 d/b/a Amedisys Home
Health
	  	404 West Main St	  	Stroud	  	OK	  	74079-3614	  	37-7642	  	2043
							
	 Amedisys Oklahoma, LLC
 d/b/a Amedisys Home
Health
	  	2209 Boren Boulevard	  	Seminole	  	OK	  	74868-1927	  	37-7642	  	2042
							
	 Amedisys Oklahoma, LLC
 d/b/a Amedisys Home
Health
	  	427 E. Cherokee Ave, Suite 3	  	Enid	  	OK	  	73701-5823	  	37-7642	  	2040

  
 48 

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	 Amedisys Oklahoma, LLC
 d/b/a Amedisys Home
Health
	  	1609 N. Strong Blvd, Suite 200	  	McAlester	  	OK	  	74501-3881	  	37-7642	  	2041
							
	 Amedisys Oklahoma, LLC
 d/b/a Amedisys Home
Health
	  	424 S. Mustang Road, Suite A	  	Yukon	  	OK	  	73099-7315	  	37-7642	  	2039
							
	 Amedisys Oklahoma, LLC
 d/b/a Amedisys Home
Health
	  	1212 Merrick Dr.	  	Ardmore	  	OK	  	73401-1824	  	37-7642	  	2044
							
	 Amedisys Pennsylvania, L.L.C.
 d/b/a Amedisys
Home Health
	  	620 Freedom Business Center, Suite 100	  	King of Prussia	  	PA	  	19406-1330	  	39-7780	  	2623
							
	 Amedisys Pennsylvania, L.L.C.
 d/b/a Amedisys
Home Health
 1605 N. Cedar Crest Blvd
	  	1605 N. Cedar Crest Blvd, Suite 509	  	Allentown	  	PA	  	18104-2355	  	39-7780	  	2625
							
	 Amedisys SC, L.L.C.
 d/b/a Amedisys Home Health
of Lexington
	  	714 South Lake Drive, Suite 250	  	Lexington	  	SC	  	29072-3433	  	42-7039	  	2211
							
	 Amedisys SC, L.L.C.
 d/b/a Amedisys Home Health
of Orangeburg
	  	1704 Village Park Drive	  	Orangeburg	  	SC	  	29118-2401	  	42-7039	  	2213

  
 49 

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	 Amedisys SC, L.L.C.
 d/b/a Amedisys Home Health
of Sumter
	  	3481 Declaration Blvd	  	Sumter	  	SC	  	29154-8140	  	42-7039	  	2214
							
	 Amedisys SC, L.L.C.
 d/b/a Amedisys Home Health
of Newberry
	  	184 Commerce Dr.	  	Newberry	  	SC	  	29108-2964	  	42-7039	  	2212
							
	 Amedisys Home Health, Inc. of South Carolina

d/b/a Amedisys Home Health of Greenville
	  	440 Roper Mountain Road, Suite G-1	  	Greenville	  	SC	  	29615-4235	  	42-7116	  	2223
							
	 Amedisys Home Health, Inc. of South Carolina

d/b/a Amedisys Home Health of Clinton
	  	210 Physicians Park Dr, Suite U	  	Clinton	  	SC	  	29325-7563	  	42-7116	  	2204
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	100 Physicians Way, Suite 240	  	Lebanon	  	TN	  	37090-8108	  	44-7206	  	0507
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	230 Cumberland Bend, Suite D	  	Nashville	  	TN	  	37228-1804	  	44-7206	  	0506
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	880 Greenlea Blvd, Suite A	  	Gallatin	  	TN	  	37066-3282	  	44-7206	  	0508

  
 50 

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	2690 Madison Street, Suite 200	  	Clarksville	  	TN	  	37043-5498	  	44-7206	  	0532
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	437 Henslee Drive	  	Dickson	  	TN	  	37055-2166	  	44-7206	  	0528
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	342 W. Central Avenue	  	Jamestown	  	TN	  	38556-3407	  	44-7260	  	0530
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	508 West Main Street	  	Livingston	  	TN	  	38570-1718	  	44-7260	  	0523
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	236 Miller Avenue, Suite 102	  	Crossville	  	TN	  	38555-4036	  	44-7260	  	0533
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	20039 Alberta St, Suite D	  	Oneida	  	TN	  	37841-3501	  	44-7260	  	0531
							
	 Amedisys Tennessee, LLC
 d/b/a Amedisys Home
Health
	  	315 N. Washington Ave, Suite 255	  	Cookeville	  	TN	  	38501-2697	  	44-7260	  	0544
							
	 HHC, Inc.
 d/b/a Amedisys Home Health
Care
	  	 6645 Stage Rd,

Suite 102
	  	Bartlett	  	TN	  	38134-3828	  	44-7451	  	5509
							
	 Amedisys Home Health, Inc. of Virginia
 d/b/a
Amedisys Home Health Care
	  	16009 Porterfield Highway	  	Abingdon	  	VA	  	24210-8471	  	49-7566	  	1703

  
 51 

													
	 Amedisys Care Center Name
	  	 Street Address
	  	 City
	  	State	  	Zip
Code	  	Medicare
Provider
Number	  	Amedisys
Identifier
	 Amedisys Home Health, Inc. of Virginia
 d/b/a
Amedisys Home Health of Duffield
	  	372 Technology Trail Lane, Suite 103	  	Duffield	  	VA	  	24244-5330	  	49-7566	  	1702
							
	 Amedisys Home Health, Inc. of Virginia
 d/b/a
Amedisys Home Health of Clintwood
	  	909 West Main Street, Suite B	  	Clintwood	  	VA	  	24228-2130	  	49-7566	  	1709

  
 52EX-10.2

 Exhibit 10.2 

CORPORATE INTEGRITY AGREEMENT 

BETWEEN THE 
 OFFICE OF
INSPECTOR GENERAL 
 OF THE 

DEPARTMENT OF HEALTH AND HUMAN SERVICES 

AND 
 AMEDISYS, INC. AND
AMEDISYS HOLDING, LLC 
  

	I.	PREAMBLE 

 Amedisys, Inc. and Amedisys Holding, LLC (collectively,
“Amedisys”) hereby enter into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and
written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements). Contemporaneously with this CIA, Amedisys is entering into a Settlement
Agreement with the United States. 
 Amedisys has maintained a voluntary compliance program for many years. The Compliance Program currently
includes, among other things, a Chief Compliance Officer, a Compliance Committee, a Code of Conduct, written policies and procedures, a disclosure program that allows for the confidential disclosure and investigation of potential compliance
violations, screening measures for Ineligible Persons (as defined below), regular compliance training for employees, various compliance auditing programs, oversight from Amedisys’s Board of Directors, and compliance risk evaluation and
mitigation procedures. Amedisys represents that its compliance program was and continues to be aimed at Amedisys’s goal of promoting the highest standards of professionalism, ethics, and integrity in the delivery of care and the conduct of
Amedisys’s business practices. Amedisys will continue to operate its compliance program throughout the term of this CIA, may modify its compliance program when it deems appropriate (subject to the terms of this CIA), and will ensure that its
compliance program complies with this CIA. 

	II.	TERM AND SCOPE OF THE CIA 

 A. The period of the compliance obligations assumed by
Amedisys under this CIA shall be five years from the effective date of this CIA. The “Effective Date” shall be the date on which the final signatory of this CIA executes this CIA. Each one-year period, beginning with the one-year period
following the Effective Date, shall be referred to as a “Reporting Period.” 
 B. Sections VII, X, and XI shall expire no later
than 120 days after OIG’s receipt of: (1) Amedisys’s final annual report; or (2) any additional materials submitted by Amedisys pursuant to OIG’s request, whichever is later. 

C. The scope of this CIA shall be governed by the following definitions: 

 

	 	1.	“Covered Persons” includes: 

  

	 	a.	all owners of Amedisys who are natural persons (other than shareholders who: (1) have an ownership interest of less than 5% and (2) acquired the ownership interest through public trading), officers, directors,
and employees of Amedisys; and 

  

	 	b.	all contractors, subcontractors, agents, and other persons who provide patient care items or patient care services or who perform billing or coding functions on behalf of Amedisys, excluding vendors whose sole
connection with Amedisys is selling or otherwise providing medical supplies or equipment to Amedisys and who do not bill the Federal health care programs for such medical supplies or equipment. 

Notwithstanding the above, this term does not include part-time or per diem employees, contractors, subcontractors, agents, and other persons
who are not reasonably expected to work more than 160 hours per year, except that any such individuals shall become “Covered Persons” at the point when they work more than 160 hours during the calendar year. 

2. “Relevant Covered Persons” includes Covered Persons involved in the delivery of patient care items or services to patients
receiving home health benefits, the preparation or submission of such claims for reimbursement from any Federal health care program, and/or the internal review or auditing of such claims submitted to any Federal health care program. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 2 

 3. “Covered Administrators” includes Covered Persons who are an administrator of a home
health care center, currently titled Directors of Operations within the Amedisys system. 
 4. “Home health care center” includes
any site or location from which Amedisys provides home health services. 
  

	III.	CORPORATE INTEGRITY OBLIGATIONS  

 Amedisys shall maintain a Compliance
Program that includes the following elements: 
 A. Compliance Officer and Committee 

1. Compliance Officer. Amedisys has a Compliance Officer and shall maintain a Compliance Officer for the term of the CIA. The Compliance
Officer shall continue to be responsible for developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program requirements. The Compliance
Officer shall continue to be a member of senior management of Amedisys, shall report directly to the Chief Executive Officer of Amedisys, shall make periodic (at least quarterly) reports regarding compliance matters directly to the Board of
Directors of Amedisys (or a Committee of the Board), and shall be authorized to report on such matters to the Board of Directors at any time. Written documentation of the Compliance Officer’s reports to the Board of Directors shall be made
available to OIG upon request. The Compliance Officer shall not be or be subordinate to the General Counsel or Chief Financial Officer. The Compliance Officer shall be responsible for monitoring the day-to-day compliance activities engaged in by
Amedisys as well as for any reporting obligations created under this CIA. Any noncompliance job responsibilities of the Compliance Officer shall be limited and must not interfere with the Compliance Officer’s ability to perform the duties
outlined in this CIA. 
 Amedisys shall report to OIG, in writing, any change in the identity of the Compliance Officer, or any actions or
changes that would affect the Compliance Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within five days after such a change. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 3 

 2. Compliance Committee. Amedisys has a Compliance Committee. The Compliance Committee
shall, at a minimum, include the Compliance Officer and other members of senior management necessary to meet the requirements of this CIA (e.g., senior executives of relevant departments, such as billing, clinical, human resources, audit, and
operations). The Compliance Officer shall chair the Compliance Committee and the Committee shall support the Compliance Officer in fulfilling his/her responsibilities (e.g., shall assist in the analysis of the Amedisys’s risk areas and
shall oversee monitoring of internal and external audits and investigations). The Compliance Committee shall meet at least quarterly. The minutes of the Compliance Committee meetings shall be made available to OIG upon request. 

Amedisys shall report to OIG, in writing, any changes in the composition of the Compliance Committee, or any actions or changes that would
affect the Compliance Committee’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 

3. Board of Directors Compliance Obligations. The Amedisys Board of Directors, acting through its Compliance and Ethics Committee
(Committee), shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Committee must include independent (i.e., non-executive) members. 

The Committee shall, at a minimum, be responsible for the following: 
  

	 	a.	meeting at least quarterly to review and oversee Amedisys’s Compliance Program, including but not limited to the performance of the Compliance Officer and Compliance Committee; and 

 

	 	b.	for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Committee summarizing its review and oversight of Amedisys’s compliance with Federal health care program requirements and
the obligations of this CIA. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 4 

 At minimum, the resolution shall include the following language: 

“The Board of Directors’ Compliance and Ethics Committee has made a reasonable inquiry into the operations of Amedisys’s
Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board’s Compliance and Ethics Committee has concluded that, to the best of its knowledge, Amedisys has
implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.” 
 If the
Committee is unable to provide such a conclusion in the resolution, the Committee shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective
Compliance Program at Amedisys. 
 Amedisys shall report to OIG, in writing, any changes in the composition of the Committee, or any actions
or changes that would affect the Committee’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 

4. Management Accountability and Certifications. Amedisys shall continue to make compliance a component of each Covered
Administrators’ performance evaluation. In addition to the responsibilities set forth in this CIA for all Covered Persons, all Covered Administrators are specifically expected to continue to monitor and oversee activities within their areas of
authority and shall annually certify in writing or electronically that, to the best of their knowledge, their facility or functional area is in material compliance with applicable Federal health care program requirements and the obligations of this
CIA. 
 For each Reporting Period, each Covered Administrator shall certify in writing or electronically that: “I have been trained on
and understand the compliance requirements and responsibilities as they relate to [insert name of care center], an area under my supervision. My job responsibilities include ensuring compliance with regard to the [insert name of care center]. To the
best of my knowledge, except as otherwise described herein, the [insert name of care center] is in material compliance with applicable Federal health care program requirements and the obligations of the CIA.” 

If any Covered Administrator is unable to provide such a conclusion in the certification, the Covered Administrator shall include in the
certification a written explanation of the reasons why he or she is unable to provide the conclusion and the steps being taken to address the issue(s) identified in the certification. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 5 

 B. Written Standards 

1. Code of Conduct. Amedisys has developed and implemented a written Code of Conduct. Within 90 days after the Effective Date, Amedisys
shall distribute the Code of Conduct to all Covered Persons. Amedisys shall continue to make the promotion of, and adherence to, the Code of Conduct an element in evaluating the performance of all employees. The Code of Conduct shall, at a minimum,
set forth: 
  

	 	a.	Amedisys’s commitment to full compliance with all Federal health care program requirements, including its commitment to prepare and submit accurate claims consistent with such requirements; 

 

	 	b.	Amedisys’s requirement that all of its Covered Persons shall be expected to comply with all Federal health care program requirements and with Amedisys’s own Policies and Procedures; 

 

	 	c.	the requirement that all of Amedisys’s Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by Amedisys, suspected violations of any Federal health care
program requirements or of Amedisys’s own Policies and Procedures; and 

  

	 	d.	the right of all individuals to use the Disclosure Program described in Section III.F, and Amedisys’s commitment to nonretaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such
disclosures. 

 Within 120 days after the Effective Date, each Covered Person shall certify, in writing or in electronic form,
that he or she has received, read, understood, and shall abide by Amedisys’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete the required certification within 30 days after becoming a Covered Person or
within 120 days after the Effective Date, whichever is later. 
 Amedisys shall periodically review the Code of Conduct to determine if
revisions are appropriate and shall make any necessary revisions based on such review. The Code of Conduct shall be distributed at least annually to all Covered Persons. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 6 

 2. Policies and Procedures. Amedisys has implemented written Policies and Procedures
regarding the operation of its compliance program. Within 90 days after the Effective Date, Amedisys shall supplement its written Policies and Procedures to include any additional compliance program requirements outlined in this CIA and any material
Federal health care program requirements that are not otherwise already contained in Amedisys’s existing Policies and Procedures. 

Within 90 days after the Effective Date, the Policies and Procedures shall be distributed to all Covered Persons. Appropriate and
knowledgeable staff shall be available to explain the Policies and Procedures. 
 At least annually (and more frequently, if appropriate),
Amedisys shall assess and update, as necessary, the Policies and Procedures. Within 30 days after the effective date of any revisions, a description of the revisions shall be communicated to all affected Covered Persons and any revised Policies and
Procedures shall be made available to all Covered Persons. 
 C. Training and Education  

1. General Training. Within 90 days after the Effective Date, Amedisys shall provide at least one hour of General Training to each
Covered Person. This training, at a minimum, shall explain Amedisys’s: 
  

	 	a.	CIA requirements; and 

  

	 	b.	Compliance Program, including the Code of Conduct. 

 New Covered Persons shall receive the
General Training described above within 30 days after becoming a Covered Person or within 90 days after the Effective Date, whichever is later. After receiving the initial General Training described above, each Covered Person shall receive at least
one hour of General Training in each subsequent Reporting Period. 
 2. Specific Training. Within 90 days after the Effective Date,
each Relevant Covered Person shall receive at least two hours of Specific Training in addition to the General Training required above. This Specific Training shall include a discussion of: 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 7 

	 	a.	the Federal health care program requirements regarding the accurate coding and submission of home health claims; 

  

	 	b.	policies, procedures, and other requirements applicable to the documentation of medical records; 

  

	 	c.	the personal obligation of each individual involved in the claims submission process to ensure that such claims are accurate; 

  

	 	d.	applicable reimbursement statutes, regulations, and program requirements and directives; 

  

	 	e.	the legal sanctions for violations of the Federal health care program requirements; and 

  

	 	f.	examples of proper and improper claims submission practices. 

 New Relevant Covered Persons
shall receive this training within 30 days after the beginning of their employment or becoming Relevant Covered Persons, or within 90 days after the Effective Date, whichever is later. 

After receiving the initial Specific Training described in this section, each Relevant Covered Person shall receive at least one hour of
Specific Training, in addition to the General Training, in each subsequent Reporting Period. 
 3. Board Member Training. Within 90
days after the Effective Date, Amedisys shall provide at least two hours of training to each member of the Board of Directors, in addition to the General Training. This training shall address the responsibilities of board members and corporate
governance. 
 New members of the Board of Directors shall receive the Board Member Training described above within 30 days after becoming a
member or within 90 days after the Effective Date, whichever is later. 
 4. Certification. Each individual who is required to attend
training shall certify, in writing or in electronic form, that he or she has received the required training. The certification shall specify the type of training received and the date received. The Compliance Officer (or designee) shall retain the
certifications, along with all course materials. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 8 

 5. Qualifications of Trainer. Persons providing the training shall be knowledgeable about
the subject area. 
 6. Update of Training. Amedisys shall review the training annually, and, where appropriate, update the training
to reflect changes in Federal health care program requirements, any issues discovered during internal audits or the Claims Review, and any other relevant information. 

7. Computer-based Training. If Amedisys chooses to provide computer-based training, it shall make available appropriately qualified and
knowledgeable staff or trainers to answer questions or provide additional information to the individuals receiving such training. In addition, if Amedisys chooses to provide computer-based General or Specific training, all applicable requirements to
provide a number of “hours” of trainings in this Section may be met with respect to computer-based training by providing the required number of “normative” hours as that term is used in the computer-based training industry. 

D. Internal Risk Evaluation and Mitigation Program 

1. Amedisys has developed and implemented numerous compliance risk evaluation and mitigation procedures. Amedisys shall, within 6 months after
the Effective Date, develop an internal Risk Evaluation and Mitigation Program (REM Program) that shall contain, at a minimum, the following elements: 
  

	 	a.	an identification of the material Medicare compliance risk areas for Amedisys’s home health services, based upon internal compliance audits, matters submitted to Amedisys’s Disclosure Program, IRO reviews, and
other appropriate internal risk assessments (Risk Evaluation); 

  

	 	b.	a risk mitigation plan that outlines risk mitigation activities that will be performed and tracked for each risk identified in the Risk Evaluation (Risk Mitigation Plan); and 

 

	 	c.	a system that monitors and tracks the implementation of the Risk Mitigation Plan (Monitoring System) to confirm that the specified mitigation activities are implemented and the results are reported to the Compliance
Officer. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 9 

 2. Amedisys, at its discretion, may retain the services of an independent consultant to assist
with the development of or modifications to the REM Program. 
 3. The REM Program shall be reviewed by an independent reviewer, as discussed
below in Section III.E and Appendix B. 
 E. Review Procedures 

 

	 	1.	General Description 

  

	 	a.	Engagement of Independent Review Organization. Within 90 days after the Effective Date, Amedisys shall engage an entity (or entities), such as an accounting, auditing, or consulting firm (hereinafter
“Independent Review Organization” or “IRO”), to perform the reviews listed in this Section III.E. The applicable requirements relating to the IRO are outlined in Appendix A to this CIA, which is incorporated by reference.

  

	 	b.	Retention of Records. The IRO and Amedisys shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and
Amedisys) related to the reviews. 

  

	 	2.	Reviews 

 a. Claims Review. The IRO shall review Amedisys’s home health
coding, billing, and claims submission to the Medicare program and the reimbursement received (Claims Review) and shall prepare a Claims Review Report, as outlined in Appendix B to this CIA, which is incorporated by reference. For each Reporting
Period, the IRO shall randomly select ten home health care centers to assess and review. The ten home health care centers selected for the Reporting Period shall be known as the “Subject Facilities.” 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 10 

 b. REM Program Review. The IRO shall review Amedisys’s REM Program and shall prepare
a REM Program Review Report, as outlined in Appendix B to this CIA, which is incorporated by reference. Amedisys may engage an IRO to review the REM Program that is different from the IRO engaged to perform the Claims Review. 

3. Unallowable Cost Review. If applicable, for the first Reporting Period, the IRO shall conduct a review of Amedisys’s compliance
with the unallowable cost provisions of the Settlement Agreement. The IRO shall determine whether Amedisys has complied with its obligations not to charge to, or otherwise seek payment from, federal or state payors for unallowable costs (as defined
in the Settlement Agreement) and its obligation to identify to applicable federal or state payors any unallowable costs included in payments previously sought from the United States, or any state Medicaid program. This unallowable costs analysis
shall include, but not be limited to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted by Amedisys or any affiliates. To the extent that such cost reports, cost statements, information
reports, or payment requests, even if already settled, have been adjusted to account for the effect of the inclusion of the unallowable costs, the IRO shall determine if such adjustments were proper. In making this determination, the IRO may need to
review cost reports and/or financial statements from the year in which the Settlement Agreement was executed, as well as from previous years. 

4. Unallowable Cost Review Report. The IRO shall prepare a report based upon the Unallowable Cost Review performed (Unallowable Cost
Review Report). The Unallowable Cost Review Report shall include the IRO’s findings and supporting rationale regarding the Unallowable Cost Review and whether Amedisys has complied with its obligation not to charge to, or otherwise seek payment
from, federal or state payors for unallowable costs (as defined in the Settlement Agreement) and its obligation to identify to applicable federal or state payors any unallowable costs included in payments previously sought from such payor. 

5. Validation Review. In the event OIG has reason to believe that: (a) Amedisys’s Claims Review or Unallowable Cost Review
fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review
or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 11 

 
Cost Review results are inaccurate (Validation Review). Amedisys shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of
Reports submitted as part of Amedisys’s final Annual Report shall be initiated no later than one year after Amedisys’s final submission (as described in Section II) is received by OIG. 

Prior to initiating a Validation Review, OIG shall notify Amedisys of its intent to do so and provide a written explanation of why OIG
believes such a review is necessary. To resolve any concerns raised by OIG, Amedisys may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any
additional information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review.
Amedisys agrees to provide any additional information as may be requested by OIG under this Section III.E.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review issues with Amedisys prior to
conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG. 

6. Independence and Objectivity Certification. The IRO shall include in its report(s) to Amedisys a certification that the IRO has
(a) evaluated its professional independence and objectivity with respect to the reviews conducted under this Section III.E and (b) concluded that it is, in fact, independent and objective, in accordance with the requirements specified in
Appendix A to this CIA. 
 F. Disclosure Program 

Amedisys has established a Disclosure Program that includes a mechanism (e.g., a toll-free compliance telephone line) to enable
individuals to disclose, to the Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Amedisys’s policies, conduct, practices, or procedures
with respect to a Federal health care program believed by the individual to be a potential violation of criminal, civil, or administrative law. Amedisys shall continue to appropriately publicize the existence of the disclosure mechanism
(e.g., via periodic e-mails to employees or by posting the information in prominent common areas). 
 The Disclosure Program shall
continue to emphasize a nonretribution, nonretaliation policy, and shall continue to include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 12 

 
of a disclosure, the Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Compliance Officer (or designee) shall make a preliminary, good
faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so
that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Amedisys shall conduct an internal review of the allegations set forth
in the disclosure and ensure that proper follow-up is conducted. 
 The Compliance Officer (or designee) shall maintain a disclosure log,
which shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. 

G. Ineligible Persons 
  

	 	1.	Definitions. For purposes of this CIA: 

  

	 	a.	an “Ineligible Person” shall include an individual or entity who: 

 i. is currently
excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs; or 

ii. has been convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded,
debarred, suspended, or otherwise declared ineligible. 
  

	 	b.	“Exclusion Lists” include: 

 i. the HHS/OIG List of Excluded Individuals/Entities
(available through the Internet at http://www.oig.hhs.gov); and 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 13 

 ii. the General Services Administration’s System for Award Management (available through
the Internet at http://www.sam.gov). 
 2. Screening Requirements. Amedisys shall continue to ensure that all prospective and
current Covered Persons are not Ineligible Persons, by implementing the following screening requirements. 
  

	 	a.	Amedisys shall continue to screen all prospective Covered Persons against the Exclusion Lists prior to engaging their services and, as part of the hiring or contracting process, shall require such Covered Persons to
disclose whether they are Ineligible Persons. 

  

	 	b.	Amedisys shall screen all Covered Persons against the Exclusion Lists within 90 days after the Effective Date and on a monthly basis thereafter. 

 

	 	c.	Amedisys shall implement a policy requiring all Covered Persons to disclose immediately any debarment, exclusion, suspension, or other event that makes that person an Ineligible Person. 

Nothing in Section III.G affects Amedisys’s responsibility to refrain from (and liability for) billing Federal health care programs for
items or services furnished, ordered, or prescribed by excluded persons. Amedisys understands that items or services furnished, ordered or prescribed by excluded persons are not payable by Federal health care programs and that Amedisys may be liable
for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether Amedisys meets the requirements of Section III.G. 

3. Removal Requirement. If Amedisys has actual notice that a Covered Person has become an Ineligible Person, Amedisys shall remove such
Covered Person from responsibility for, or involvement with, Amedisys’s business operations related to the Federal health care programs and shall remove such Covered Person from any position for which the Covered Person’s compensation or
the items or services furnished, ordered, or prescribed by the Covered Person are paid in whole or part, directly or indirectly, by Federal health care programs or otherwise with Federal funds at least until such time as the Covered Person is
reinstated into participation in the Federal health care programs. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 14 

 4. Pending Charges and Proposed Exclusions. If Amedisys has actual notice that a Covered
Person is charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract term or, Amedisys shall take all
appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary, patient, or resident, or any claims submitted to any Federal health care program.

 H. Notification of Government Investigation or Legal Proceedings 

Within 30 days after discovery, Amedisys shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Amedisys
conducted or brought by a governmental entity or its agents involving an allegation that Amedisys has committed a crime or has engaged in fraudulent activities. This notification shall include a description of the allegation, the identity of the
investigating or prosecuting agency, and the status of such investigation or legal proceeding. Amedisys shall also provide written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the
findings and/or results of the investigation or proceedings, if any. 
 I. Repayment of Overpayments 

1. Definition of Overpayments. For purposes of this CIA, an “Overpayment” shall mean the amount of money Amedisys has received
for home health services in excess of the amount due and payable under any Federal health care program requirements. 
 2. Repayment of
Overpayments 
  

	 	a.	 If, at any time, Amedisys identifies or learns of any Overpayment, Amedisys shall repay the Overpayment to the appropriate payor (e.g.,
Medicare contractor) within 60 days after identification of the Overpayment and take remedial steps within 90 days after identification (or such additional time as may be agreed to by the payor) to correct the problem, including preventing the
underlying problem and the Overpayment from recurring. If not yet quantified, within 60 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 15 

	 	
days after identification, Amedisys shall notify the payor of its efforts to quantify the Overpayment amount along with a schedule of when such work is expected to be completed. Notification and
repayment to the payor shall be done in accordance with the payor’s policies. 

  

	 	b.	Notwithstanding the above, notification and repayment of any Overpayment amount that routinely is reconciled or adjusted pursuant to policies and procedures established by the payor should be handled in accordance with
such policies and procedures. 

 J. Reportable Events 

1. Definition of Reportable Event. For purposes of this CIA, a “Reportable Event” means anything that involves: 

 

	 	a.	a substantial Overpayment; 

  

	 	b.	a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized;

  

	 	c.	the employment of or contracting with a Covered Person who is an Ineligible Person as defined by Section III.G.1.a; or 

  

	 	d.	the filing of a bankruptcy petition by Amedisys. 

 A Reportable Event may be the result of an isolated event or
a series of occurrences. 
 2. Reporting of Reportable Events. If Amedisys determines (after a reasonable opportunity to conduct an
appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Amedisys shall notify OIG, in writing, within 30 days after making the determination that the Reportable Event exists. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 16 

 3. Reportable Events under Section III.J.1.a. For Reportable Events under Section
III.J.1.a, the report to OIG shall be made within 30 days of the identification of the Overpayment, and shall include: 
  

	 	a.	a description of the steps taken by Amedisys to identify and quantify the Overpayment; 

  

	 	b.	a complete description of the Reportable Event, including the relevant facts, persons involved, and legal and Federal health care program authorities implicated; 

 

	 	c.	a description of Amedisys’s actions taken to correct the Reportable Event; and 

  

	 	d.	any further steps Amedisys plans to take to address the Reportable Event and prevent it from recurring. 

Within 60 days of identification of the Overpayment, Amedisys shall provide OIG with a copy of the notification and repayment (if quantified) to the payor
required in Section III.I.2. 
 4. Reportable Events under Section III.J.1.b and c. For Reportable Events under Section III.J.1.b and
III.J.1.c, the report to OIG shall include: 
  

	 	a.	a complete description of the Reportable Event, including the relevant facts, persons involved, and legal and Federal health care program authorities implicated; 

 

	 	b.	a description of Amedisys’s actions taken to correct the Reportable Event; 

  

	 	c.	any further steps Amedisys plans to take to address the Reportable Event and prevent it from recurring; and 

  

	 	d.	if the Reportable Event has resulted in an Overpayment, a description of the steps taken by Amedisys to identify and quantify the Overpayment. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 17 

 5. Reportable Events under Section III.J.1.d. For Reportable Events under Section
III.J.1.d, the report to the OIG shall include documentation of the bankruptcy filing and a description of any Federal health care program authorities implicated. 

6. Reportable Events Involving the Stark Law. Notwithstanding the reporting requirements outlined above, any Reportable Event
that involves only a probable violation of section 1877 of the Social Security Act, 42 U.S.C. §1395nn (the Stark Law) should be submitted by Amedisys to the Centers for Medicare & Medicaid Services (CMS) through the self-referral
disclosure protocol (SRDP), with a copy to the OIG. The requirements of Section III.I.2 that require repayment to the payor of any identified Overpayment within 60 days shall not apply to any Overpayment that may result from a probable
violation of only the Stark Law that is disclosed to CMS pursuant to the SRDP. If Amedisys identifies a probable violation of the Stark Law and repays the applicable Overpayment directly to the CMS contractor, then Amedisys is not required by this
Section III.J to submit the Reportable Event to CMS through the SRDP. 
  

	IV.	SUCCESSOR LIABILITY; CHANGES TO BUSINESS UNITS OR LOCATIONS 

 A. Sale of
Business, Business Unit or Location. 
 In the event that, after the Effective Date, Amedisys proposes to sell any or all of its home
health business, business units or locations (whether through a sale of assets, sale of stock, or other type of transaction) that are subject to this CIA, Amedisys shall notify OIG of the proposed sale at least 30 days prior to the sale of its
business, business unit or location. This notification shall include a description of the business, business unit or location to be sold, a brief description of the terms of the sale, and the name and contact information of the prospective
purchaser. This CIA shall be binding on the purchaser as it relates to the acquired business, business unit or location, unless otherwise determined and agreed to in writing by the OIG. 

B. Change or Closure of Business, Business Unit or Location 

In the event that, after the Effective Date, Amedisys changes home health locations or closes a home health business, business unit or location
related to the furnishing of items or services that may be reimbursed by Federal health care programs, Amedisys shall notify OIG of this fact as soon as possible, but no later than within 30 days after the date of change or closure of the business,
business unit or location. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 18 

 C. Purchase or Establishment of New Business, Business Unit or Location 

In the event that, after the Effective Date, Amedisys purchases or establishes a new home health business, business unit or location related to
the furnishing of items that may be reimbursed by Federal health care programs, Amedisys shall notify OIG at least 30 days prior to such purchase or the operation of the new business, business unit or location. This notification shall include the
address of the new business, business unit or location, phone number, fax number, the location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program
contractor to which Amedisys currently submits claims. Each new home health business, business unit or location and all Covered Persons at each new home health business, business unit or location shall be subject to the applicable requirements of
this CIA, unless otherwise agreed to in writing by the OIG. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 19 

	V.	IMPLEMENTATION AND ANNUAL REPORTS 

 A. Implementation Report 

Within 120 days after the Effective Date, Amedisys shall submit a written report to OIG summarizing the status of its implementation of the
requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 
 1. the name, address, phone
number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 

2. the names and positions of the members of the Compliance Committee required by Section III.A; 

3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section
III.A.3; 
 4. the names of the Covered Administrators and the identity of their respective home health care center who are responsible for
satisfying the Management Accountability and Certifications described in Section III.A.4; 
 5. a copy of Amedisys’s Code of Conduct
required by Section III.B.1; 
 6. the number of individuals required to complete the Code of Conduct certification required by Section
III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 

7. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG
upon request); 
 8. the following information regarding each type of training required by Section III.C: 

 

	 	a.	a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 20 

	 	b.	the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. 

A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 

9. a description of the Disclosure Program required by Section III.F; 

10. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter;
(c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between Amedisys and the IRO; and (e) a
certification from the IRO regarding its professional independence and objectivity with respect to Amedisys; 
 11. a description of the
process by which Amedisys fulfills the requirements of Section III.G regarding Ineligible Persons; 
 12. a list of all of Amedisys’s
home health locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider
number and/or supplier number(s); the name and address of each Medicare and state Medicaid program contractor to which Amedisys currently submits claims; and the name of the Administrator for the location; 

13. a description of Amedisys’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their
respective lines of business; and 
 14. the certifications required by Section V.C. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 21 

 B. Annual Reports 

Amedisys shall submit to OIG annually a report with respect to the status of, and findings regarding, Amedisys’s compliance activities for
each of the five Reporting Periods (Annual Report). Each Annual Report shall include, at a minimum: 
 1. any change in the identity,
position description, or other noncompliance job responsibilities of the Compliance Officer and any change in the membership of the Compliance Committee described in Section III.A; 

2. the dates of each report made by the Compliance Officer to the Board (written documentation of such reports shall be made available upon
request); 
 3. the Board resolution required by Section III.A.3; 

4. the number of individuals required to execute the Covered Administrator certification required by Section III.A.4; the percentage of
individuals who did not execute, or were unable to execute, the certification and the reasons therefore; and, if applicable, an explanation of the efforts by Amedisys to overcome the exceptions; 

5. a summary of any changes or amendments to Amedisys’s Code of Conduct required by Section III.B.1 and the reason for such changes, along
with a copy of the revised Code of Conduct; 
 6. the number of individuals required to complete the Code of Conduct certification required
by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request); 

7. a summary of any significant changes or amendments to the Policies and Procedures required by Section III.B and the reasons for such changes
(e.g., change in contractor policy); 
 8. the following information regarding each type of training required by Section III.C: 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 22 

	 	a.	a description of the initial and annual training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; 

 

	 	b.	the number of individuals required to complete the initial and annual training, the percentage of individuals who actually completed the initial and annual training, and an explanation of any exceptions.

 A copy of all training materials and the documentation to support this information shall be made available to OIG upon request; 

8. in the first Annual Report, a description of the REM Program, and, in the remaining Annual Reports, a summary of any significant changes to
the REM Program; 
 9. a complete copy of all reports prepared pursuant to Section III.E, along with a copy of the IRO’s engagement
letter; 
 10. Amedisys’s response to the reports prepared pursuant to Section III.E, along with corrective action plan(s) related to
any issues raised by the reports; 
 11. a summary and description of any and all current and prior engagements and agreements between
Amedisys and the IRO (if different from what was submitted as part of the Implementation Report); 
 12. a certification from the IRO
regarding its professional independence and objectivity with respect to Amedisys; 
 13. a summary of Reportable Events (as defined in
Section III.J) identified during the Reporting Period and the status of any corrective action relating to all such Reportable Events; 
 14.
a report of the aggregate Overpayments that have been returned to the Federal health care programs. Overpayment amounts shall be broken down into the following categories: inpatient Medicare, outpatient Medicare, Medicaid (report each applicable
state separately, if applicable), and other Federal health care programs. Overpayment amounts that are routinely reconciled or adjusted pursuant to policies and procedures established by the payor do not need to be included in this aggregate
Overpayment report; 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 23 

 15. a summary of the disclosures in the disclosure log required by Section III.F that relate to
Federal health care programs (the complete disclosure log shall be made available to OIG upon request); 
 16. any changes to the process by
which Amedisys fulfills the requirements of Section III.G regarding Ineligible Persons; 
 17. a summary describing any ongoing investigation
or legal proceeding required to have been reported pursuant to Section III.H. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal
proceeding; 
 18. a description of all changes to the most recently provided list of Amedisys’s locations (including addresses) as
required by Section V.A.12; the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number(s) and/or supplier number(s);
and the name and address of each Medicare and state Medicaid program contractor to which Amedisys currently submits claims; and 
 19. the
certifications required by Section V.C. 
 The first Annual Report shall be received by OIG no later than 90 days after the end of the first
Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report. 

C. Certifications 
 The
Implementation Report and each Annual Report shall include a certification by the Compliance Officer that: 
 1. to the best of his or her
knowledge, except as otherwise described in the report, Amedisys is in compliance with all of the requirements of this CIA; 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 24 

 2. he or she has reviewed the report and has made reasonable inquiry regarding its content and
believes that the information in the report is accurate and truthful; and 
 3. to the best of his or her knowledge, Amedisys has complied
with its obligations under the Settlement Agreement: (a) not to resubmit to any Federal health care program payors any previously denied claims related to the Covered Conduct addressed in the Settlement Agreement, and not to appeal any such
denials of claims; (b) not to charge to or otherwise seek payment from federal or state payors for unallowable costs (as defined in the Settlement Agreement); and (c) to identify and adjust any past charges or claims for unallowable costs.

 D. Designation of Information 

Amedisys shall clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or
financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. Amedisys shall refrain from identifying any information as exempt from disclosure if that
information does not meet the criteria for exemption from disclosure under FOIA. 
  

	VI.	NOTIFICATIONS AND SUBMISSION OF REPORTS 

 Unless otherwise stated in writing after
the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: 
 OIG: 

Administrative and Civil Remedies Branch 

Office of Counsel to the Inspector General 

Office of Inspector General 

U.S. Department of Health and Human Services 

Cohen Building, Room 5527 
 330
Independence Avenue, S.W. 
 Washington, DC 20201 

Telephone: 202.619.2078 

Facsimile: 202.205.0604 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 25 

 Amedisys: 

Jeffrey D. Jeter 
 Chief
Compliance Officer 
 Amedisys, Inc. 

5959 South Sherwood Forest Boulevard 

Baton Rouge, Louisiana 70816 

Telephone: 225.292.2031 

Facsimile: 225.292.8163 
 Unless
otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement,
internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, Amedisys may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document
format (pdf), in addition to a paper copy. 
  

	VII.	OIG INSPECTION, AUDIT, AND REVIEW RIGHTS 

 In addition to any other rights OIG may
have by statute, regulation, or contract, OIG or its duly authorized representative(s) may examine or request copies of Amedisys’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of
Amedisys’s locations for the purpose of verifying and evaluating: (a) Amedisys’s compliance with the terms of this CIA; and (b) Amedisys’s compliance with the requirements of the Federal health care programs. The
documentation described above shall be made available by Amedisys to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized
representative(s) may interview any of Amedisys’s employees, contractors, or agents who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed
upon between the individual and OIG. Amedisys shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Amedisys’s employees may elect to be interviewed with
or without a representative of Amedisys present. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 26 

	VIII.	 DOCUMENT AND RECORD RETENTION 

 Amedisys shall maintain for inspection all
documents and records relating to reimbursement from the Federal health care programs and to compliance with this CIA for six years (or longer if otherwise required by law) from the Effective Date. 

 

	IX.	DISCLOSURES  

 Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R.
Part 5, OIG shall make a reasonable effort to notify Amedisys prior to any release by OIG of information submitted by Amedisys pursuant to its obligations under this CIA and identified upon submission by Amedisys as trade secrets, or information
that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Amedisys shall have the rights set forth at 45 C.F.R. § 5.65(d). 

 

	X.	BREACH AND DEFAULT PROVISIONS  

 Amedisys is expected to fully and timely
comply with all of its CIA obligations. 
 A. Stipulated Penalties for Failure to Comply with Certain Obligations 

As a contractual remedy, Amedisys and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the
imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 

1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Amedisys fails
to establish and implement any of the following obligations as described in Section III: 
  

	 	a.	a Compliance Officer; 

  

	 	b.	a Compliance Committee; 

  

	 	c.	the Board of Directors and Covered Administrators compliance obligations; 

  

	 	d.	a written Code of Conduct; 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 27 

	 	e.	written Policies and Procedures; 

  

	 	f.	the training of Covered Persons, Relevant Covered Persons, and Board Members; 

  

	 	g.	the REM Program; 

  

	 	h.	a Disclosure Program; 

  

	 	i.	Ineligible Persons screening and removal requirements; 

  

	 	j.	notification of Government investigations or legal proceedings; and 

  

	 	k.	reporting of Reportable Events. 

 2. A Stipulated Penalty of $2,500 (which shall begin to
accrue on the day after the date the obligation became due) for each day Amedisys fails to engage and use an IRO, as required in Section III.E, Appendix A, and Appendix B. 

3. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Amedisys
fails to submit the Implementation Report or any Annual Reports to OIG in accordance with the requirements of Section V by the deadlines for submission. 

4. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Amedisys
fails to submit any Claims Review Report, the REM Program Review Report, or Unallowable Cost Review Report in accordance with the requirements of Section III.E and Appendix B. 

5. A Stipulated Penalty of $1,500 for each day Amedisys fails to grant access as required in Section VII. (This Stipulated Penalty shall begin
to accrue on the date Amedisys fails to grant access.) 
 6. A Stipulated Penalty of $50,000 for each false certification submitted by or on
behalf of Amedisys as part of its Implementation Report, Annual Report, additional documentation to a report (as requested by the OIG), or otherwise required by this CIA. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 28 

 7. A Stipulated Penalty of $1,000 for each day Amedisys fails to comply fully and adequately with
any obligation of this CIA. OIG shall provide notice to Amedisys stating the specific grounds for its determination that Amedisys has failed to comply fully and adequately with the CIA obligation(s) at issue and steps Amedisys shall take to comply
with the CIA. (This Stipulated Penalty shall begin to accrue 10 days after Amedisys receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG
has sought a Stipulated Penalty under Subsections 1- 6 of this Section. 
 B. Timely Written Requests for Extensions 

Amedisys may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification
or report required by this CIA. Notwithstanding any other provision in this Section, if OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the
notification or report shall not begin to accrue until one day after Amedisys fails to meet the revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for
failure to perform the act or file the notification or report shall not begin to accrue until three business days after Amedisys receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written
request” is defined as a request in writing received by OIG at least five business days prior to the date by which any act is due to be performed or any notification or report is due to be filed. 

C. Payment of Stipulated Penalties 

1. Demand Letter. Upon a finding that Amedisys has failed to comply with any of the obligations described in Section X.A and after
determining that Stipulated Penalties are appropriate, OIG shall notify Amedisys of: (a) Amedisys’s failure to comply; and (b) OIG’s exercise of its contractual right to demand payment of the Stipulated Penalties. (This
notification shall be referred to as the “Demand Letter.”) 
 2. Response to Demand Letter. Within 10 days after the
receipt of the Demand Letter, Amedisys shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable Stipulated Penalties or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s
determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Amedisys elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Amedisys cures, to OIG’s
satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for exclusion under Section X.D.

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 29 

 3. Form of Payment. Payment of the Stipulated Penalties shall be made by electronic funds
transfer to an account specified by OIG in the Demand Letter. 
 4. Independence from Material Breach Determination. Except as set
forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that Amedisys has materially breached this CIA, which decision shall be made at OIG’s discretion
and shall be governed by the provisions in Section X.D, below. 
 D. Exclusion for Material Breach of this CIA 

1. Definition of Material Breach. A material breach of this CIA means: 

 

	 	a.	a repeated or flagrant violation of the obligations under this CIA, including, but not limited to, the obligations addressed in Section X.A; 

 

	 	b.	a failure by Amedisys to report a Reportable Event, take corrective action, and make the appropriate refunds, as required in Section III.J; 

 

	 	c.	a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in accordance with Section X.C; or 

  

	 	d.	a failure to engage and use an IRO in accordance with Section III.E, Appendix A, and Appendix B. 

2. Notice of Material Breach and Intent to Exclude. The parties agree that a material breach of this CIA by Amedisys constitutes an
independent basis for Amedisys’s exclusion from participation in the Federal health care programs. Upon a determination by OIG that Amedisys has materially breached this CIA and that exclusion is the appropriate remedy, OIG shall notify
Amedisys of: (a) Amedisys’s material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion. (This notification shall be referred to as the “Notice of Material Breach and Intent to Exclude.”)

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 30 

 3. Opportunity to Cure. Amedisys shall have 30 days from the date of receipt of the Notice
of Material Breach and Intent to Exclude to demonstrate to OIG’s satisfaction that: 
  

	 	a.	Amedisys is in compliance with the obligations of the CIA cited by OIG as being the basis for the material breach; 

  

	 	b.	the alleged material breach has been cured; or 

  

	 	c.	the alleged material breach cannot be cured within the 30 day period, but that: (i) Amedisys has begun to take action to cure the material breach; (ii) Amedisys is pursuing such action with due diligence; and
(iii) Amedisys has provided to OIG a reasonable timetable for curing the material breach. 

 4. Exclusion Letter.
If, at the conclusion of the 30 day period, Amedisys fails to satisfy the requirements of Section X.D.3, OIG may exclude Amedisys from participation in the Federal health care programs. OIG shall notify Amedisys in writing of its determination to
exclude Amedisys. (This letter shall be referred to as the “Exclusion Letter.”) Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of Amedisys’s receipt of the
Exclusion Letter. The exclusion shall have national effect. Reinstatement to program participation is not automatic. After the end of the period of exclusion, Amedisys may apply for reinstatement by submitting a written request for reinstatement in
accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004. 
 E. Dispute Resolution 

1. Review Rights. Upon OIG’s delivery to Amedisys of its Demand Letter or of its Exclusion Letter, and as an agreed-upon
contractual remedy for the resolution of disputes arising under this CIA, Amedisys shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the
Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS
Departmental Appeals Board (DAB), in a manner consistent with the 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 31 

 
provisions in 42 C.F.R. § 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made within 10 days
after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. 

2. Stipulated Penalties Review. Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal
Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Amedisys was in full and timely compliance with the obligations of this CIA for which OIG demands payment; and (b) the period of
noncompliance. Amedisys shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ decision related to Stipulated Penalties.
If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Amedisys to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless Amedisys requests
review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its decision. 

3. Exclusion Review. Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations,
the only issues in a proceeding for exclusion based on a material breach of this CIA shall be: 
  

	 	a.	whether Amedisys was in material breach of this CIA; 

  

	 	b.	whether such breach was continuing on the date of the Exclusion Letter; and 

  

	 	c.	whether the alleged material breach could not have been cured within the 30-day period, but that: (i) Amedisys had begun to take action to cure the material breach within that period; (ii) Amedisys has pursued
and is pursuing such action with due diligence; and (iii) Amedisys provided to OIG within that period a reasonable timetable for curing the material breach and Amedisys has followed the timetable. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 32 

 For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision
favorable to OIG, or, if the ALJ rules for Amedisys, only after a DAB decision in favor of OIG. Amedisys’s election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to exclude Amedisys upon the issuance of
an ALJ’s decision in favor of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that Amedisys may
request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Amedisys shall waive its right to any notice of such an exclusion
if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Amedisys, Amedisys shall be reinstated effective on the date of the original exclusion. 

4. Finality of Decision. The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any
statutes or regulations. Consequently, the parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this CIA. 

 

	XI.	EFFECTIVE AND BINDING AGREEMENT 

 Amedisys and OIG agree as follows: 

A. This CIA shall become final and binding on the date the final signature is obtained on the CIA. 

B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.

 C. OIG may agree to a suspension of Amedisys’s obligations under this CIA based on a certification by Amedisys that it is no longer
providing health care items or services that will be billed to any Federal health care program and that it does not have any ownership or control interest, as defined in 42 U.S.C. §1320a-3, in any entity that bills any Federal health care
program. If Amedisys is relieved of its CIA obligations, Amedisys will be required to notify OIG in writing at least 30 days in advance if Amedisys plans to resume providing health care items or services that are billed to any Federal health care
program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified. 

D. The undersigned Amedisys signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories
represent that they are signing this CIA in their official capacities and that they are authorized to execute this CIA. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 33 

 E. This CIA may be executed in counterparts, each of which constitutes an original and all of
which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 34 

 ON BEHALF OF AMEDISYS, INC. 

 

					
	/s/ Ronald A. LaBorde	  	 	  	4.22.14
	RONALD A. LABORDE	  		  	DATE
	President and Interim Chief Executive Officer On behalf of Amedisys, Inc.	  		  	
			
	/s/ Paul B. Murphy	  		  	4.22.14
	PAUL B. MURPHY	  		  	DATE
	King & Spalding, LLP	  		  	
	Counsel for Amedisys, Inc.	  		  	

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 35 

 ON BEHALF OF AMEDISYS HOLDING, LLC 

 

					
	/s/ Ronald A. LaBorde	  		  	4.22.14
	RONALD A. LABORDE	  		  	DATE
	President and Interim Chief Executive Officer	  		  	
	On behalf of Amedisys Holding, LLC	  		  	
			
	/s/ Paul B. Murphy	  		  	4.22.14
	PAUL B. MURPHY	  		  	DATE
	King & Spalding, LLP	  		  	
	Counsel for Amedisys Holding, LLC	  		  	

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 36 

 ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL 

OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 
  

					
	/s/ Robert K. DeConti	  		  	4.22.14
	ROBERT K. DECONTI	  		  	DATE
	Assistant Inspector General for Legal Affairs	  		  	
	Office of Inspector General	  		  	
	U. S. Department of Health and Human Services	  		  	
			
	/s/ Sarah K. Kessler	  		  	4.22.14
	SARAH K. KESSLER	  		  	DATE
	Associate Counsel	  		  	
	Office of Inspector General	  		  	
	U. S. Department of Health and Human Services	  		  	

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
  
 37 

 APPENDIX A 

INDEPENDENT REVIEW ORGANIZATION 
 This
Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the CIA. 
 A. IRO
Engagement 
 1. Amedisys shall engage an IRO (or IROs) that possesses the qualifications set forth in Paragraph B, below, to perform the
responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.10 of the CIA or
any additional information submitted by Amedisys in response to a request by OIG, whichever is later, OIG will notify Amedisys if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Amedisys may continue to engage the
IRO. 
 2. If Amedisys engages a new IRO during the term of the CIA, this IRO shall also meet the requirements of this Appendix. If a new IRO
is engaged, Amedisys shall submit the information identified in Section V.A.10 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Amedisys at the
request of OIG, whichever is later, OIG will notify Amedisys if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Amedisys may continue to engage the IRO. 

B. IRO Qualifications 
 The
IRO shall: 
 1. assign individuals to conduct the Claims Review, Risk Evaluation and Mitigation Program Review (REM Program Review), and
Unallowable Cost Review, if applicable who have expertise in the billing, coding, reporting, and other requirements of home health claims and in the general requirements of the Federal health care program(s) from which Amedisys seeks reimbursement;

 2. assign individuals to design and select the Claims Review sample who are knowledgeable about the appropriate statistical sampling
techniques; 
 3. assign individuals to design and perform the REM Program Review who are knowledgeable about Medicare compliance risk
evaluation and mitigation in home health; 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix A 

 4. assign individuals to conduct the coding review portions of the Claims Review who have a
nationally recognized coding certification and who have maintained this certification (e.g., completed applicable continuing education requirements); and 

5. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis. 

C. IRO Responsibilities 

The IRO shall: 
 1. perform each
Claims Review, REM Program Review, and Unallowable Cost review, if applicable in accordance with the specific requirements of the CIA; 
 2.
follow all applicable Medicare rules and reimbursement guidelines in making assessments in the Claims Review and REM Program Review; 
 3. if
in doubt of the application of a particular Medicare policy or regulation, request clarification from the appropriate authority (e.g., Medicare contractor); 

4. respond to all OIG inquires in a prompt, objective, and factual manner; and 

5. prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA. 

D. IRO Independence and Objectivity 

The IRO must perform the Claims Review and REM Program Review in a professionally independent and objective fashion, as defined in the most
recent Government Auditing Standards issued by the United States Government Accountability Office. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix A 

 E. IRO Removal/Termination 

1. Provider and IRO. If Amedisys terminates its IRO or if the IRO withdraws from the engagement during the term of the CIA, Amedisys
must submit a notice explaining its reasons for termination or the reason for withdrawal to OIG no later than 30 days after termination or withdrawal. Amedisys must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days
of termination or withdrawal of the IRO. 
 2. OIG Removal of IRO. In the event OIG has reason to believe the IRO does not possess the
qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG may, at its sole discretion, require Amedisys to engage a new IRO
in accordance with Paragraph A of this Appendix. Amedisys must engage a new IRO within 60 days of termination of the IRO. 
 Prior to
requiring Amedisys to engage a new IRO, OIG shall notify Amedisys of its intent to do so and provide a written explanation of why OIG believes such a step is necessary. To resolve any concerns raised by OIG, Amedisys may present additional
information regarding the IRO’s qualifications, independence or performance of its responsibilities. OIG will attempt in good faith to resolve any differences regarding the IRO with Amedisys prior to requiring Amedisys to terminate the IRO.
However, the final determination as to whether or not to require Amedisys to engage a new IRO shall be made at the sole discretion of OIG. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix A 

 APPENDIX B 
  

	I.	CLAIMS REVIEW 

 A. Claims Review. The IRO shall perform the Claims Review annually
to cover each of the five Reporting Periods. The IRO shall perform all components of each Claims Review. 
 1. Definitions. For the
purposes of the Claims Review, the following definitions shall be used: 
  

	 	a.	Overpayment: The amount of money Amedisys has received in excess of the amount due and payable under any Federal health care program requirements, as determined by the IRO in connection with the claims reviews
performed under this Appendix B, and which shall include any extrapolated Overpayments determined in accordance with Section A.3 of this Appendix B. 

  

	 	b.	Paid Claim: A claim submitted by Amedisys and for which Amedisys has received reimbursement from Medicare. 

  

	 	c.	Population: The Population shall be defined as all Paid Claims for the Subject Facilities during the 12-month period covered by the Claims Review. 

 

	 	d.	Error Rate: The Error Rate shall be the percentage of net Overpayments identified in the sample. The net Overpayments shall be calculated by subtracting all underpayments identified in the sample from all gross
Overpayments identified in the sample. (Note: Any potential cost settlements or other supplemental payments should not be included in the net Overpayment calculation. Rather, only underpayments identified as part of the Discovery Sample shall be
included as part of the net Overpayment calculation.) 

 The Error Rate is calculated by dividing the net Overpayment
identified in the sample by the total dollar amount associated with the Paid Claims in the sample. 
  

	 	e.	Home Health Care Center: All Amedisys’ locations using the same provider number. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix B 

 2. Discovery Sample. The IRO shall randomly select and review a sample of 30 Paid Claims
from each of the Subject Facilities, for a total of 300 Paid Claims (Discovery Sample). The Paid Claims shall be reviewed based on the supporting documentation available to Amedisys or under Amedisys’s control and applicable billing and coding
regulations and guidance to determine whether the claim was correctly coded, submitted, and reimbursed. 
 If the Error Rate (as defined
above) for the Discovery Sample is less than 5%, no additional sampling is required, nor is the Systems Review required. (Note: The guidelines listed above do not imply that this is an acceptable error rate. Accordingly, Amedisys should, as
appropriate, further analyze any errors identified in the Discovery Sample. Amedisys recognizes that OIG or other HHS component, in its discretion and as authorized by statute, regulation, or other appropriate authority may also analyze or review
Paid Claims included, or errors identified, in the Discovery Sample or any other segment of the universe.) 
 3. Full Sample. If the
Discovery Sample indicates that the Error Rate is 5% or greater, the IRO shall select an additional sample of Paid Claims from the Subject Facilities (Full Sample) using commonly accepted sampling methods. The Paid Claims selected for the Full
Sample shall be reviewed based on supporting documentation available to Amedisys or under Amedisys’s control and applicable billing and coding regulations and guidance to determine whether the claim was correctly coded, submitted, and
reimbursed. For purposes of calculating the size of the Full Sample, the Discovery Sample may serve as the probe sample, if statistically appropriate. Additionally, the IRO may use the Paid Claims sampled as part of the Discovery Sample, and the
corresponding findings for those Paid Claims, as part of its Full Sample, if: (1) statistically appropriate and (2) the IRO selects the Full Sample Paid Claims using the seed number generated by the Discovery Sample. The findings of the
Full Sample shall be used by the IRO to estimate the actual Overpayment in the Population with a 90% confidence level and with a maximum relative precision of 25% of the point estimate. OIG, in its sole discretion, may refer the findings of the Full
Sample (and any related workpapers) received from Amedisys to the appropriate Federal health care program payor (e.g., Medicare contractor), for appropriate follow-up by that payor. 

4. Systems Review. If Amedisys’s Discovery Sample identifies an Error Rate of 5% or greater, Amedisys’s IRO shall also conduct
a Systems Review. The Systems Review shall consist of the following: 
  

	 	a.	a review of Amedisys’s billing and coding systems and processes relating to claims submitted to Federal health care programs (including, but not limited to, the operation of the billing system, the process by which
claims are coded, safeguards to ensure proper coding, claims submission and billing; and procedures to identify and correct inaccurate coding and billing); 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix B 

	 	b.	for each claim in the Discovery Sample and Full Sample that resulted in an Overpayment, the IRO shall review the system(s) and process(es) that generated the claim and identify any problems or weaknesses that may have
resulted in the identified Overpayments. The IRO shall provide its observations and recommendations on suggested improvements to the system(s) and the process(es) that generated the claim. 

5. Other Requirements. 
  

	 	a.	Supplemental Materials. The IRO shall request all documentation and materials required for its review of the Paid Claims selected as part of the Discovery Sample or Full Sample (if applicable), and Amedisys
shall furnish such documentation and materials to the IRO prior to the IRO initiating its review of the Discovery Sample or Full Sample (if applicable). If the IRO accepts any supplemental documentation or materials from Amedisys after the IRO
has completed its initial review of the Discovery Sample or Full Sample (if applicable) (Supplemental Materials), the IRO shall identify in the Claims Review Report the Supplemental Materials, the date the Supplemental Materials were accepted, and
the relative weight the IRO gave to the Supplemental Materials in its review. In addition, the IRO shall include a narrative in the Claims Review Report describing the process by which the Supplemental Materials were accepted and the IRO’s
reasons for accepting the Supplemental Materials. 

  

	 	b.	Paid Claims without Supporting Documentation. Any Paid Claim for which Amedisys cannot produce any documentation to support the Paid Claim shall be considered an error and the total reimbursement received by
Amedisys for such Paid Claim shall be deemed an Overpayment. Replacement sampling for Paid Claims with missing documentation is not permitted. 

  

	 	c.	Use of First Samples Drawn. For the purposes of all samples (Discovery Sample(s) and Full Sample(s)) discussed in this Appendix, the Paid Claims selected in each first sample shall be used (i.e., it is not
permissible to generate more than one list of random samples and then select one for use with the Discovery Sample or Full Sample). 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix B 

 6. Repayment of Identified Overpayments. Amedisys shall repay within 30 days any
Overpayment(s) identified in the Discovery Sample, regardless of the Error Rate, and (if applicable) the Full Sample, including the IRO’s estimate of the actual Overpayment in the Population as determined in accordance with Section A.3 above,
in accordance with payor refund policies. Amedisys shall make available to OIG all documentation that reflects the refund of the Overpayment(s) to the payor. 

B. Claims Review Report. The IRO shall prepare a Claims Review Report as described in this Appendix for each Claims Review performed.
The following information shall be included in the Claims Review Report for each Discovery Sample and Full Sample (if applicable). 
 1.
Claims Review Methodology. 
  

	 	a.	Claims Review Population. A description of the Population subject to the Claims Review. 

  

	 	b.	Claims Review Objective. A clear statement of the objective intended to be achieved by the Claims Review. 

  

	 	c.	Source of Data. A description of the specific documentation relied upon by the IRO when performing the Claims Review (e.g., medical records, physician orders, certificates of medical necessity, requisition
forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare carrier or intermediary manual or bulletins (including issue and date), other policies, regulations, or
directives). 

  

	 	d.	Review Protocol. A narrative description of how the Claims Review was conducted and what was evaluated. 

  

	 	e.	Supplemental Materials. A description of any Supplemental Materials as required by A.5.a., above. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix B 

 2. Statistical Sampling Documentation. 

 

	 	a.	A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO. 

 

	 	b.	A copy of the statistical software printout(s) estimating how many Paid Claims are to be included in the Full Sample, if applicable. 

 

	 	c.	A description or identification of the statistical sampling software package used to select the sample and determine the Full Sample size, if applicable. 

3. Claims Review Findings. 
  

	 	a.	Narrative Results 

 i. A description of Amedisys’s billing and coding system(s),
including the identification, by position description, of the personnel involved in coding and billing. 
 ii. A narrative explanation of
the IRO’s findings and supporting rationale (including reasons for errors, patterns noted, etc.) regarding the Claims Review, including the results of the Discovery Sample, and the results of the Full Sample (if any). 

 

	 	b.	Quantitative Results 

 i. Total number and percentage of instances in which the IRO
determined that the Paid Claims submitted by Amedisys (Claim Submitted) differed from what should have been the correct claim (Correct Claim), regardless of the effect on the payment. 

ii. Total number and percentage of instances in which the Claim Submitted differed from the Correct Claim and in which such difference
resulted in an Overpayment to Amedisys. 
 iii. Total dollar amount of all Overpayments in the Discovery Sample and the Full Sample (if
applicable). 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix B 

 iv. Total dollar amount of Paid Claims included in the Discovery Sample and the Full Sample and
the net Overpayment associated with the Discovery Sample and the Full Sample. 
 v. Error Rate in the Discovery Sample and the Full Sample.

 vi. A spreadsheet of the Claims Review results that includes the following information for each Paid Claim: Federal health care program
billed, beneficiary health insurance claim number, date of service, code submitted (e.g., DRG, CPT code, etc.), code reimbursed, allowed amount reimbursed by payor, correct code (as determined by the IRO), correct allowed amount (as
determined by the IRO), dollar difference between allowed amount reimbursed by payor and the correct allowed amount. 
 vii. If a Full
Sample is performed, the methodology used by the IRO to estimate the actual Overpayment in the Population and the amount of such Overpayment. 
  

	 	c.	Recommendations. The IRO’s report shall include any recommendations for improvements to Amedisys’s billing and coding system based on the findings of the Claims Review. 

4. Systems Review Findings. The IRO shall prepare a Systems Review Report based on the Systems Review performed (if applicable) that
shall include the IRO’s observations, findings, and recommendations regarding: 
  

	 	a.	the strengths and weaknesses in Amedisys’s billing systems and processes; 

  

	 	b.	the strengths and weaknesses in Amedisys’s coding systems and processes; and 

  

	 	c.	possible improvements to Amedisys’s billing and coding systems and processes to address the specific problems or weaknesses that resulted in the identified Overpayments. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix B 

 5. Credentials. The names and credentials of the individuals who: (1) designed the
statistical sampling procedures and the review methodology utilized for the Claims Review and (2) performed the Claims Review. 
  

	II.	RISK EVALUATION AND MITIGATION PROGRAM REVIEW 

 A. Risk Evaluation and Mitigation
Program Review. The applicable IRO shall perform the Risk Evaluation and Mitigation Program Review (REM Program Review) annually to cover all Reporting Periods. The IRO shall perform all components of each REM Program Review. 

B. Elements. The REM Program Review shall consist of the following: 

1. a review of the processes by which Amedysis develops its Risk Evaluation and Risk Mitigation Plan, including the sources of information used
to develop each; and a determination of whether Amedisys has identified the material Medicare compliance risk areas; 
 2. an assessment of
whether, in developing the Risk Evaluation and Risk Mitigation Plan, additional or different sources or types of data or information should be utilized; and a determination of whether risk mitigation activities are appropriate to address identified
risk areas; 
 3. a review of the experience and background of the persons responsible for development of the Risk Evaluation and the Risk
Mitigation Plan and an assessment of the completeness and appropriateness of the training, policies, procedures, standard operating procedures, and guidance such individual receives regarding the development of each; and 

4. an assessment of whether the Monitoring System adequately and effectively monitors and tracks the activities identified in the Risk
Mitigation Plan to ensure that such activities are implemented and the results reported to the Compliance Officer. 
 C. REM Program
Review Report. The IRO shall prepare a report based upon REM Program Review (REM Program Review Report). The REM Program Review Report will include: 

1. the IRO’s findings, observations, and recommendations as outlined in Section II.B above; and 

2. the names and credentials of the individuals who performed the REM Program Review. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix B 

 D. Access. No later than 120 days before the end of each Reporting Period, Amedisys shall
provide the IRO with full access to the REM Program to permit the REM Program Review. 

  
 Amedisys, Inc. and Amedisys Holding, LLC
Corporate Integrity Agreement 
 Appendix B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]